<SEC-DOCUMENT>0001193125-21-209928.txt : 20210707
<SEC-HEADER>0001193125-21-209928.hdr.sgml : 20210707
<ACCEPTANCE-DATETIME>20210707164432
ACCESSION NUMBER:		0001193125-21-209928
CONFORMED SUBMISSION TYPE:	S-1
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20210707
DATE AS OF CHANGE:		20210707

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Trevi Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001563880
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				450834299
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		S-1
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-257747
		FILM NUMBER:		211077889

	BUSINESS ADDRESS:	
		STREET 1:		195 CHURCH STREET
		STREET 2:		14TH FLOOR
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
		BUSINESS PHONE:		203-304-2499

	MAIL ADDRESS:	
		STREET 1:		195 CHURCH STREET
		STREET 2:		14TH FLOOR
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06510
</SEC-HEADER>
<DOCUMENT>
<TYPE>S-1
<SEQUENCE>1
<FILENAME>d153682ds1.htm
<DESCRIPTION>S-1
<TEXT>
<HTML><HEAD>
<TITLE>S-1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>As filed with Securities and Exchange Commission on July&nbsp;7, 2021 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="right"><B>Registration
<FONT STYLE="white-space:nowrap">No.&nbsp;333-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT> </B></P> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES
AND EXCHANGE COMMISSION </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, D.C. 20549 </B></P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>FORM <FONT
STYLE="white-space:nowrap">S-1</FONT> </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>REGISTRATION STATEMENT </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>UNDER </I></B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I>THE
SECURITIES ACT OF&nbsp;1933 </I></B></P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:22pt; font-family:Times New Roman" ALIGN="center"><B>TREVI THERAPEUTICS,&nbsp;INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="34%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>2834</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B><FONT STYLE="white-space:nowrap">45-0834299</FONT></B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(State or other jurisdiction of<BR>incorporation&nbsp;or&nbsp;organization)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Primary Standard Industrial<BR>Classification Code Number)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(I.R.S. Employer<BR>Identification Number)</B></TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>195 Church Street, 14th Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New Haven, Connecticut 06510 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(203) <FONT STYLE="white-space:nowrap">304-2499</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address, including zip code, and telephone number, including area code, of registrant&#146;s principal executive offices) </B></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Jennifer L. Good </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>President
and Chief Executive Officer </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Trevi Therapeutics,&nbsp;Inc. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>195 Church Street, 14th Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>New Haven, Connecticut 06510 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(203) <FONT STYLE="white-space:nowrap">304-2499</FONT> </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Name, address, including zip code, and telephone number, including area code, of agent for service) </B></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><I>Copies to: </I></B></P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Stuart
M. Falber </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>60 State Street </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Boston,
Massachusetts 02109 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">(617)&nbsp;526-6000</FONT> </B></P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Approximate date of commencement of proposed sale to public: </B>From time to time after this Registration Statement becomes effective, as determined by the
selling stockholder. </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule&nbsp;415
under the Securities Act of 1933 check the following box.&nbsp;&nbsp;&#9746; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is filed to register additional securities for an offering
pursuant to Rule&nbsp;462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective amendment filed pursuant to Rule&nbsp;462(c) under the Securities Act, check the following box and list the Securities Act
registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If this Form is a post-effective
amendment filed pursuant to Rule&nbsp;462(d) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.&nbsp;&nbsp;&#9744; </P>
<P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a <FONT STYLE="white-space:nowrap">non-accelerated</FONT>
filer, a smaller reporting company or an emerging growth company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer,&#148; &#147;smaller reporting company&#148; and &#147;emerging growth company&#148; in <FONT
STYLE="white-space:nowrap">Rule&nbsp;12b-2</FONT> of the Exchange Act. </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="17%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="2%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9744;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"><FONT STYLE="white-space:nowrap">Non-accelerated&nbsp;filer</FONT></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Emerging&nbsp;growth&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&#9746;</TD></TR>
</TABLE> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period
for complying with any new or revised financial accounting standards provided pursuant to Section&nbsp;7(a)(2)(B) of the Securities Act.&nbsp;&nbsp;&#9746; </P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:2pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>CALCULATION OF
REGISTRATION FEE </B></P> <P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="95%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="14%"></TD></TR>


<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Title of Each Class&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Securities&nbsp;to Be Registered</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Amount</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>to&nbsp;be</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Registered(1)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;Price</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Per&nbsp;Share(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Proposed</B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Maximum<BR>Aggregate</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Offering&nbsp;Price(2)</B></P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"><B>Amount of<BR>Registration&nbsp;Fee</B></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:8pt; font-family:Times New Roman">Common stock, par value $0.001 per share</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000">5,170,088</TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">$2.16 </P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">$11,167,390.08</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-LEFT:1px solid #000000; BORDER-TOP:1px solid #000000">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="BORDER-TOP:1px solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">$1,218.37</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD COLSPAN="9" VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD></TR>
</TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Represents 170,088 shares previously issued to the selling stockholder and up to 5,000,000 shares that are
issuable at the option of the registrant pursuant to a purchase agreement with the selling stockholder. The shares will be offered for resale by the selling stockholder. Pursuant to Rule 416(a) under the Securities Act of 1933 (the &#147;Securities
Act&#148;), this registration statement also covers any additional number of shares of common stock issuable upon stock splits, stock dividends, dividends or other distribution, recapitalization or similar events with respect to the shares of common
stock being registered pursuant to this registration statement. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman; " ALIGN="left">Estimated solely for purposes of calculating the registration fee pursuant to Rule 457(c) under the Securities
Act, based on average of high and low price per share of the common stock as reported on the Nasdaq Global Select Market on July&nbsp;2, 2021. </P></TD></TR></TABLE> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>The Registrant hereby amends
this Registration Statement on such date or dates as may be necessary to delay its effective date until the Registrant shall file&nbsp;a further amendment which specifically states that this Registration Statement shall thereafter become effective
in accordance with Section&nbsp;8(a) of the Securities Act or until the Registration Statement shall become effective on such date as the Commission, acting pursuant to said Section&nbsp;8(a), may determine. </B></P>
<P STYLE="font-size:2pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#ff4338"><B>The information in this prospectus is not complete and may be changed. The selling
stockholder named in this prospectus may not sell these securities until the registration statement filed with the Securities and Exchange Commission is effective. This prospectus is not an offer to sell these securities and the selling stockholder
named in this prospectus is not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not permitted. </B></FONT></P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT COLOR="#ff4338"><B>Subject to completion, dated July&nbsp;7, 2021 </B></FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g153682g58r98.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>5,170,088 Shares of Common Stock </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the resale, from time to time, of up to 5,170,088 shares of our common stock, par value $0.001 per share, by the selling
stockholder, Lincoln Park Capital Fund, LLC, which we refer to as Lincoln Park or the selling stockholder. The shares of common stock to which this prospectus relates includes shares that have been or may be issued to Lincoln Park pursuant to a
purchase agreement between us and Lincoln Park dated June&nbsp;18, 2021, which we refer to as the &#147;Purchase Agreement&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are not selling any
securities under this prospectus and we will not receive any proceeds from the sale of the shares by Lincoln Park. However, we may receive proceeds of up to $15,000,000 from the sale of certain of the shares to Lincoln Park under the Purchase
Agreement, from time to time in our discretion after the date the registration statement of which this prospectus is a part is declared effective and after satisfaction of other conditions in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park is an &#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act of 1933, as amended, or the Securities Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lincoln Park may sell the shares of common stock described in this prospectus in a number of different ways and at varying prices. See &#147;Plan of
Distribution&#148; on page 24 for more information about how Lincoln Park may sell the shares of common stock being registered pursuant to this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have agreed to bear all of the expenses incurred in connection with the registration of the shares to which this prospectus relates. Lincoln Park will pay
or assume discounts, commissions, and fees of underwriters, selling brokers or dealer managers, if any, incurred in connection with the sale of shares of our common stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market, or Nasdaq, under the symbol &#147;TRVI.&#148; On July&nbsp;6, 2021, the closing sale price of
our common stock as reported on Nasdaq was $2.18. You are urged to obtain current market quotations for the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are an &#147;emerging growth
company&#148; and a &#147;smaller reporting company&#148; under applicable Securities and Exchange Commission rules and, as such, have elected to comply with certain reduced public company disclosure requirements for this prospectus and future
filings. See &#147;Prospectus Summary&#151;Implications of Being an Emerging Growth Company and a Smaller Reporting Company.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Our business and
investment in our common stock involve significant risks. These risks are described in the section titled &#147;<U><A HREF="#rom153682_4">Risk Factors</A></U>&#148; beginning on page&nbsp;7 of this prospectus. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the
accuracy or adequacy of this prospectus. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="97%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_2">PROSPECTUS SUMMARY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_3">THE OFFERING</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_4">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_5">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND INDUSTRY
DATA</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_6">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_7">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_8">THE LINCOLN PARK TRANSACTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_9">THE SELLING STOCKHOLDER</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_10">DESCRIPTION OF CAPITAL STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">20</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_11">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">24</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_12">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_13">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_14">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom153682_15">INCORPORATION OF CERTAIN DOCUMENTS BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC. Before making your investment
decision, we urge you to carefully read this prospectus and all of the information contained in the documents incorporated by reference in this prospectus, as well as the additional information described under the headings &#147;Where You Can Find
More Information&#148; and &#147;Incorporation of Certain Documents by Reference.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent there is a conflict between the information
contained in this prospectus, on the one hand, and the information contained in any document incorporated by reference in this prospectus, on the other hand, you should rely on the information in this prospectus, provided that if any statement in
one of these documents is inconsistent with a statement in another document having a later date&#151;for example, a document incorporated by reference in this prospectus&#151;the statement in the document having the later date modifies or supersedes
the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any
document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreement, and should not be deemed to be a
representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately
representing the current state of our affairs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have not, and the selling stockholder has not, authorized anyone to provide you with any information
other than that contained in or incorporated by reference in this prospectus, any prospectus supplement or in any related free writing prospectus filed by us with the SEC. This prospectus does not constitute an offer to sell or the solicitation of
an offer to buy any securities other than the securities described in this prospectus or an offer to sell or the solicitation of an offer to buy such securities in any circumstances in which such offer or solicitation is unlawful. You should assume
that the information appearing in this prospectus, any prospectus supplement, the documents incorporated by reference and any related free writing prospectus is accurate only as of their respective dates. Our business, financial condition, results
of operations and prospects may have changed materially since those dates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_2"></A>PROSPECTUS SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This summary highlights, and is qualified in its entirety by, the more detailed information included elsewhere in this prospectus or incorporated by
reference. This summary does not contain all of the information that may be important to you. You should read and carefully consider the entire prospectus, especially the &#147;Risk Factors&#148; section of this prospectus, before deciding to invest
in our common stock. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Overview </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are a
clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (nalbuphine ER) to treat serious neurologically mediated conditions. We are developing Haduvio for the treatment of
chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, or IPF. We are also developing Haduvio in levodopa-induced dyskinesia, or LID, in patients with Parkinson&#146;s disease. These
conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems. Due to nalbuphine&#146;s mechanism of action as a modulator of opioid receptors, we believe it has the potential to be
effective in treating each of these conditions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Lincoln Park Transaction </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2021, we and Lincoln Park entered into the Purchase Agreement and a registration rights agreement, or the Registration Rights Agreement. The
Purchase Agreement provides that, subject to the terms and conditions set forth therein, we may sell to Lincoln Park up to $15.0&nbsp;million of shares of common stock from time to time during the term of the Purchase Agreement. Pursuant to the
terms of the Registration Rights Agreement, we have filed the registration statement of which this prospectus is a part to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Purchase Agreement, on June&nbsp;18, 2021 we issued 170,088 shares of our common stock to Lincoln Park as
commitment shares, or the Commitment Shares, as consideration for Lincoln Park&#146;s commitment to purchase shares of our common stock under the Purchase Agreement. The Commitment Shares are included in the 5,170,088 shares of common stock being
registered under the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the terms and subject to the conditions of the Purchase Agreement,
we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase from us, up to $15.0&nbsp;million of shares of our common stock. Such sales of common stock by us, if any, will be subject to certain
limitations, and may occur from time to time, at our sole discretion, over a <FONT STYLE="white-space:nowrap">24-month</FONT> period commencing on the date that the registration statement of which this prospectus is a part is declared effective by
the SEC and a final prospectus in connection therewith is filed and the other conditions set forth in the Purchase Agreement are satisfied. Lincoln Park has no right to require us to sell any shares of common stock to Lincoln Park, but Lincoln Park
is obligated to make purchases as we direct, subject to conditions set forth in the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Purchase Agreement, we may from time to
time, at our discretion, direct Lincoln Park to purchase on any single business day, which we refer to as a &#147;Regular Purchase,&#148; up to (i) 100,000 shares of common stock if the closing sale price of our common stock is at least $7.50 per
share on Nasdaq, (ii) 75,000 shares of common stock if the closing sale price of our common stock is at least $5.00 per share on Nasdaq or (iii) 50,000 shares of common stock if the closing sale price of our common stock is below $5.00 per share on
Nasdaq. In any case, Lincoln Park&#146;s commitment in any single Regular Purchase may not exceed $2,000,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization,
<FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for each such Regular Purchase will be based on prevailing market prices of our
common stock immediately preceding the time of sale as computed under the Purchase Agreement. Under the Purchase Agreement, we may not effect any sales of common stock on any purchase date that the closing sale price of our common stock on Nasdaq is
less than the floor price of $0.50 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition to Regular Purchases, we may also direct Lincoln Park to purchase other amounts as accelerated
purchases or as additional accelerated purchases on the terms and subject to the conditions set forth in the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Purchase
Agreement provides that we may sell up to $15.0&nbsp;million of our common stock to Lincoln Park, only 5,170,088 of the shares of common stock that have been or may be issued to Lincoln Park are being offered under this prospectus. Depending on the
market prices of our common stock at the times we elect to issue and sell shares to Lincoln Park under the Purchase Agreement, in accordance with the terms of the Registration Rights Agreement, we may need to register for resale under the Securities
Act additional shares of our common stock in order to receive aggregate gross proceeds equal to the $15.0&nbsp;million total commitment available to us under the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under applicable rules of Nasdaq and pursuant to the terms of the Purchase Agreement, in no event may we issue or sell to Lincoln Park under the Purchase
Agreement shares of our common stock in excess of 4,175,167 shares (including the Commitment Shares), which represents 19.99% of the 20,886,283 shares of our common stock that were outstanding immediately prior to the execution of the Purchase
Agreement, or the Exchange Cap, unless (i)&nbsp;we obtain stockholder approval to issue shares of our common stock in excess of the Exchange Cap or (ii)&nbsp;the average price of all applicable sales of our common stock to Lincoln Park under the
Purchase Agreement equals or exceeds $2.18 per share (which represents the closing sale price of our common stock immediately prior to the execution of the Purchase Agreement), such that the issuances and sales of our common stock to Lincoln Park
under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasdaq rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement also prohibits us
from directing Lincoln Park to purchase any shares of our common stock if those shares, when aggregated with all other shares of common stock then beneficially owned by Lincoln Park and its affiliates, would result in Lincoln Park and its affiliates
having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Purchase Agreement
contains customary representations, warranties, covenants, indemnification and termination provisions. Lincoln Park has covenanted not to cause or engage in any manner whatsoever, any direct or indirect short selling or hedging of our common stock.
There are no limitations on use of proceeds, financial or business covenants, restrictions on future financings (other than restrictions on our ability to enter into additional &#147;equity line&#148; or a substantially similar transaction whereby a
specific investor is irrevocably bound pursuant to an agreement with us to purchase securities over a period of time from us at a price based on the market price of our common stock at the time of such purchase), rights of first refusal,
participation rights, penalties or liquidated damages in the Purchase Agreement. The Purchase Agreement may be terminated by us at any time, at our sole discretion, without any cost or penalty. During any &#147;event of default&#148; under the
Purchase Agreement, we may not initiate any purchase of shares by Lincoln Park until such event of default is cured; provided, however, Lincoln Park does not have the right to terminate the Purchase Agreement solely due to such event of default.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The net proceeds under the Purchase Agreement to us will depend on the frequency of sales and the number of shares sold to Lincoln Park and prices at
which we sell shares to Lincoln Park. We expect that any net proceeds received by us from such sales to Lincoln park will be used for working capital and general corporate purposes. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to Our Business </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our business is subject to a number of risks of which you should be aware before making an investment decision. These risks are discussed more fully in the
&#147;Risk Factors&#148; section of our Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarterly period ended March&nbsp;31, 2021, which is incorporated by reference herein. These risks include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face risks related to health epidemics and other widespread outbreaks of contagious disease, including the
novel coronavirus pandemic, or <FONT STYLE="white-space:nowrap">COVID-19,</FONT> which has delayed our ability to complete our ongoing clinical trials, disrupted our business operations and may further delay our clinical trials, interrupt our supply
chain, disrupt regulatory activities, or have other adverse effects on our business and operations. In addition, the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic has caused substantial disruption in the financial markets and economies
worldwide, which could result in adverse effects on our business and operations. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have incurred significant losses since inception, expect to incur significant and increasing losses for the
foreseeable future, and may never achieve or maintain profitability. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We will need substantial additional funding, and if we are unable to raise sufficient capital when needed on
acceptable terms, or at all, we could be forced to delay, reduce or abandon our product development programs or commercialization efforts. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have identified conditions and events that raise substantial doubt about our ability to continue as a going
concern. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our existing indebtedness, together with our other financial obligations and contractual commitments, could
adversely affect our financial condition and restrict our future operations. For instance, if we fail to receive positive data in our Phase 2b/3 PRISM trial and to meet certain equity raise requirements under our loan facility with Silicon Valley
Bank, or SVB, including raising at least $15.0 million in net proceeds from the sale of equity securities during the period from June 1, 2021 through October 31, 2021, SVB may require us to deposit unrestricted and unencumbered cash equal to 100% of
the principal amount of the indebtedness then outstanding in a cash collateral account controlled by SVB, which would reduce the amounts available to fund working capital, capital expenditures, product development efforts and other general corporate
purposes. As of June&nbsp;30, 2021, we had failed to meet the requirement to raise $12.0&nbsp;million by June&nbsp;30, 2021, and as a result, SVB has the right to cash collateralize the indebtedness under our loan facility until such time as we meet
the requirement. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We are dependent on the successful development and commercialization of Haduvio, our sole product candidate. If
we are unable to complete the clinical development of, obtain marketing approval for or successfully commercialize Haduvio, or if we experience significant delays in doing so, our business would be substantially harmed. In addition, the development
of Haduvio for the treatment of pruritus associated with prurigo nodularis is currently significantly more advanced than our other target indications. If we are not successful in developing and commercializing Haduvio for the treatment of pruritus
associated with prurigo nodularis, our business could also be substantially harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We have experienced delays and difficulties in the enrollment of patients in our clinical trials, including our
Phase 2b/3 PRISM trial and our Phase 2 CANAL trial. If we experience further delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented. Other companies are
conducting clinical trials or have announced plans for future clinical trials that are seeking, or are likely to seek, to enroll patients with prurigo nodularis, and patients are generally only able to enroll in a single trial at a time. In
addition, many patients use various treatments <FONT STYLE="white-space:nowrap">off-label</FONT> to treat pruritus associated with prurigo nodularis and these patients and their physicians may be reluctant to forgo, discontinue or otherwise alter
their use of such <FONT STYLE="white-space:nowrap">off-label</FONT> therapeutic approaches to participate in our clinical trials. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our approach to the development and commercialization of Haduvio to treat serious neurologically mediated
conditions is unproven. </P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Clinical drug development involves a lengthy and expensive process with an uncertain outcome. Even if we complete
the necessary preclinical studies and clinical trials, the regulatory approval process is expensive, time consuming and uncertain and may prevent us from obtaining approvals for the commercialization of Haduvio or any future product candidate.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Our Phase 2 clinical trial of Haduvio for the treatment of pruritus associated with prurigo nodularis may not be
predictive of the results of our PRISM trial, including due to the small patient size of the Phase 2 clinical trial, the discontinuation rate among patients in the Phase 2 clinical trial, the limited number of patients who completed treatment in the
Phase 2 clinical trial and differences in the design of the Phase 2 clinical trial and the PRISM trial, including the longer treatment period for Haduvio being used in the PRISM trial. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Adverse events or undesirable side effects caused by, or other unexpected properties of, Haduvio or any future
project candidate may be identified during development and could delay or prevent the marketing approval or limit the use of Haduvio or any future product. Haduvio, as a mixed <I></I><FONT STYLE="FONT-FAMILY:SYMBOL">&#107;</FONT>-opioid receptor
agonist and <FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>-opioid receptor antagonist, may be susceptible to side effects associated with drugs having either of those mechanisms of action, including psychiatric side effects, withdrawal effects,
respiratory depression and potential cardiac risk, as well as endocrine side effects associated with opioids generally. The drug label for nalbuphine, the active ingredient in Haduvio, carries a warning for serious, life-threatening or fatal
respiratory depression, and Haduvio, if approved for marketing in any indication, will likely carry a similar label. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Many currently approved <FONT STYLE="FONT-FAMILY:SYMBOL">&#109;</FONT>-opioid products are subject to restrictive
marketing and distribution regulations which, if applied to Haduvio, could potentially restrict its use and harm our ability to generate profits. We plan to conduct a human abuse liability, or HAL, study to further characterize the abuse potential
of oral nalbuphine. If the results of the HAL study suggest that Haduvio may carry risks of misuse, abuse or addiction, or even if the trial indicates that Haduvio does not carry such risks, the United States Food and Drug Administration, or FDA,
may require us to implement a Risk Evaluation and Mitigation Strategy in connection with any commercialization of Haduvio and the U.S. Drug Enforcement Agency could determine that Haduvio should be classified as a controlled substance.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to establish sales, marketing and distribution capabilities or enter into sales, marketing and
distribution arrangements with third parties, we may not be successful in commercializing Haduvio or any future product candidates if and when they are approved. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We face substantial competition, which may result in others developing or commercializing products before or more
successfully than we do. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We rely on third parties to conduct our clinical trials. If they do not perform satisfactorily, our business
could be harmed. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">We contract with third parties for the manufacture, storage, packaging and distribution of Haduvio for clinical
trials, including a single supplier for the active ingredient, and expect to continue to rely on third parties for these services in connection with our future development and commercialization efforts for Haduvio and any future product candidates.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we fail to comply with our obligations under our existing and any future intellectual property licenses with
third parties, including our licenses with Endo Pharmaceuticals Inc. and with Rutgers, the State University of New Jersey, we could lose license rights that are critical to our business or owe damages to the licensor of such intellectual property.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">If we are unable to obtain and maintain sufficient patent protection for Haduvio or any future product candidate,
and the disease indications for which we are developing, or may in the future develop, Haduvio, or if the scope of the patent protection is not sufficiently broad, competitors could develop
</P></TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
and commercialize products similar or identical to such product candidate, and our ability to successfully commercialize such product candidate may be adversely affected. </P></TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Information </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We were incorporated under the
laws of the State of Delaware on March&nbsp;17, 2011 under the name Trevi Therapeutics, Inc. Our principal executive offices are located at 195 Church Street, 14th Floor, New Haven, Connecticut, 06510, and our telephone number is (203) <FONT
STYLE="white-space:nowrap">304-2499.</FONT> Our website address is www.trevitherapeutics.com. The information contained on, or that can be accessed through, our website is not a part of this prospectus. We have included our website address in this
prospectus solely as an inactive textual reference. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We own or have rights to trademarks, service marks and trade names that we use in connection with the
operation of our business, including our corporate name, logos and website names. We own the trademarks Trevi<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Haduvio<SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP>. Other
trademarks, service marks and trade names appearing in this prospectus are the property of their respective owners. Solely for convenience, some of the trademarks, service marks and trade names referred to in this prospectus are listed without the <SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and <SUP STYLE="font-size:85%; vertical-align:top">&#153;</SUP> symbols, but we will assert, to the fullest extent under applicable law, our rights to our trademarks, service marks and trade
names. We intend to propose Haduvio as the trade name for our nalbuphine ER investigational product and therefore plan to use that name when we refer to nalbuphine ER going forward. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Implications of Being an Emerging Growth Company and a Smaller Reporting Company </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a company with less than $1.07&nbsp;billion of revenue during our last fiscal year, we qualify as an &#147;emerging growth company&#148; as defined in the
Jumpstart Our Business Startups Act of 2012, or the JOBS Act. We may remain an emerging growth company until December&nbsp;31, 2024 or until such earlier time as we have more than $1.07&nbsp;billion in annual revenue, the market value of our stock
held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is more than $700&nbsp;million as of the last business day of our most recently completed second fiscal quarter or we issue more than $1&nbsp;billion of
<FONT STYLE="white-space:nowrap">non-convertible</FONT> debt over a three-year period. For so long as we remain an emerging growth company, we are permitted and intend to rely on exemptions from certain disclosure and other requirements that are
applicable to other public companies that are not emerging growth companies. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are also a &#147;smaller reporting company,&#148; meaning that the market
value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> was less than $700&nbsp;million measured on the last business day of our most recently completed second fiscal quarter, and our annual revenue was less than
$100&nbsp;million during our most recently completed fiscal year. We may continue to be a smaller reporting company if either (i)&nbsp;the market value of our stock held by <FONT STYLE="white-space:nowrap">non-affiliates</FONT> is less than
$250&nbsp;million measured on the last business day of our second fiscal quarter or (ii)&nbsp;our annual revenue was less than $100&nbsp;million during the most recently completed fiscal year and the market value of our stock held by <FONT
STYLE="white-space:nowrap">non-affiliates</FONT> is less than $700&nbsp;million measured on the last business day of our second fiscal quarter. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may
continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. For so long as we remain a smaller reporting company, we are permitted and intend to rely on exemptions from certain disclosure
and other requirements that are applicable to other public companies that are not smaller reporting companies. </P>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_3"></A>THE OFFERING </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Common stock offered by selling stockholder </B></P></TD>
<TD>The shares being sold by this prospectus consist of: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">170,088 shares of our common stock issued to Lincoln Park as consideration for its commitment to purchase shares
of our common stock under the Purchase Agreement, or the Commitment Shares; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="40%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Up to 5,000,000 shares of our common stock we may sell to Lincoln Park from time to time, at our sole discretion,
over the next 24 months in accordance with the Purchase Agreement. </P></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Selling stockholder </B></P></TD>
<TD>Lincoln Park Capital Fund, LLC. See &#147;Selling Stockholder&#148; on page&nbsp;18 of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Use of proceeds </B></P></TD>
<TD>We will not receive any proceeds from the sale of common stock by Lincoln Park pursuant to this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="38%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">We may receive gross proceeds of up to $15.0&nbsp;million from the sale of shares to Lincoln Park under the Purchase Agreement after the date of this prospectus. Such proceeds will be used to fund our clinical trials,
working capital and general corporate purposes. See &#147;Use of Proceeds&#148; on page 10 of this prospectus. </TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Risk factors </B></P></TD>
<TD>You should read the &#147;Risk Factors&#148; section included or incorporated by reference in this prospectus for a discussion of factors to consider carefully before deciding to invest in shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="38%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:Times New Roman"><B>Nasdaq Global Select Market symbol </B></P></TD>
<TD>&#147;TRVI&#148; </TD></TR></TABLE>
</div><br clear="All"></div>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_4"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Investing in our common stock involves a high degree of risk. Before you decide to invest in our common stock, you should carefully consider the risks
described below and in the sections captioned &#147;Risk Factors&#148; in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and
other filings we make with the Securities and Exchange Commission, or SEC, from time to time, which are incorporated by reference herein in their entirety, together with the other information in this prospectus and the information and documents
incorporated by reference in this prospectus. If any of the risks described below or in our most recent Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> our most recent Quarterly Report on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> and the other filings incorporated by reference herein occur, our business, financial condition, results of operations and future growth prospects could be harmed. In these circumstances, the market price
of our common stock could decline, and you may lose all or part of your investment. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Risks Related to the Offering </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>The sale or issuance of shares of our common stock to Lincoln Park may cause dilution, and the sale of shares of common stock acquired by Lincoln Park,
or the perception that such sales may occur, could cause the price of our common stock to fall. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2021, we entered into the
Purchase Agreement with Lincoln Park, pursuant to which Lincoln Park has committed to purchase from us up to $15.0&nbsp;million of shares of our common stock at our discretion. As consideration for the execution of the Purchase Agreement, we issued
170,088 Commitment Shares to Lincoln Park for its commitment to purchase shares of our common stock under the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The 5,170,088 shares of
our common stock being registered for resale hereunder represent shares of our common stock that have been or may be issued and sold under the Purchase Agreement to Lincoln Park at our sole discretion from time to time over a <FONT
STYLE="white-space:nowrap">24-month</FONT> period commencing after the satisfaction of certain conditions set forth in the Purchase Agreement. The purchase price for the shares of our common stock that we may sell to Lincoln Park under the Purchase
Agreement will fluctuate based on the public trading price of our common stock. Depending on market liquidity at the time, sales of such shares of our common stock may cause the public trading price of our common stock to decrease. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We generally have the right to control the timing and amount of any future sales of shares of our common stock to Lincoln Park. Sales of shares of our common
stock, if any, to Lincoln Park will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of the additional shares of our common stock that may be available for us
to sell pursuant to the Purchase Agreement. Therefore, sales to Lincoln Park by us could result in substantial dilution to the interests of other holders of our common stock. Additionally, the sale of a substantial number of shares of our common
stock to Lincoln Park, or the anticipation of such sales, could make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect sales. If and when we do sell
shares of our common stock to Lincoln Park, after Lincoln Park has acquired the shares of common stock, Lincoln Park may resell all, some or none of those shares of common stock at any time or from time to time in its discretion. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>We may not have access to the full amount available under the Purchase Agreement with Lincoln Park. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Purchase Agreement provides that we may sell up to $15.0&nbsp;million of shares of common stock to Lincoln Park, only 5,170,088 of the shares of
common stock that have been or may be issued to Lincoln Park are being offered under this prospectus, of which an aggregate of 170,088 shares represent the Commitment Shares and of which 5,000,000 shares represent shares that may be issued and sold
to Lincoln Park in the future under the Purchase Agreement, if and when we sell shares of our common stock to Lincoln Park under the Purchase Agreement. As a result, depending on the market prices of our common stock at the times we elect to issue
and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
sell shares to Lincoln Park under the Purchase Agreement, we may be able to issue and sell more shares of our common stock to Lincoln Park pursuant to the Purchase Agreement than can be
represented by the 5,170,088 shares of common stock registered for resale under the registration statement that includes this prospectus. In such case, before we can sell any additional shares to Lincoln Park, we will need to register for resale
under the Securities Act such additional shares of common stock, which will require additional time, resources and cost to us. In addition, the issuance and sale of such additional shares of common stock could cause substantial dilution to our
stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, under the rules of the Nasdaq Global Select Market and pursuant to the terms of the Purchase Agreement, in no event may we
issue more than 19.99% of our shares outstanding under the Purchase Agreement unless we obtain stockholder approval or an exception pursuant to the rules of the Nasdaq Global Select Market is obtained to issue more than 19.99%. This limitation will
not apply in certain limited circumstances as set out in the Purchase Agreement. We are not permitted to issue any shares of common stock under the Purchase Agreement if such issuance would breach our obligations under the rules or regulations of
the Nasdaq Global Select Market. In addition, Lincoln Park cannot be required to purchase any shares of our common stock if such sale would result in Lincoln Park&#146;s beneficial ownership exceeding 9.99% of the then outstanding shares of our
common stock. Our inability to access a portion or the full amount available under the Purchase Agreement, in the absence of any other financing sources, could have a material adverse effect on our business. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Lincoln Park will pay less than the then-prevailing market price for shares of common stock, which could cause the price of our common stock to decline.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price of shares of common stock sold to Lincoln Park under the Purchase Agreement is derived from the market price of our common
stock on the Nasdaq Global Select Market. The shares of common stock to be sold to Lincoln Park pursuant to the Purchase Agreement will be purchased at a discounted price depending on the type of purchase. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Regular purchases will be purchased at a price equal to the lower of: (i)&nbsp;the lowest sale price of our common stock on the applicable purchase date and
(ii)&nbsp;the arithmetic average of the three (3)&nbsp;lowest closing sale prices for our common stock during the ten consecutive business days ending on the business day immediately preceding such purchase date (in each case, to be appropriately
adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, share split or other similar transaction that occurs on or after the date of this Agreement). Accelerated purchases will be purchased at a
price equal to 97% of the lower of (i)&nbsp;the closing sale price of our common stock on the applicable purchase date and (ii)&nbsp;the volume weighted average price of our common stock as reported on the Nasdaq Global Select Market on the
applicable purchase date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As a result of this pricing structure, Lincoln Park may sell the shares of our common stock that it receives immediately after
receipt of the shares of common stock, which could cause the price of our common stock to decrease. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_5"></A>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND
INDUSTRY DATA </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus and the information incorporated by reference in this prospectus include &#147;forward-looking statements&#148; within
the meaning of Section&nbsp;27A of the Securities Act, and Section&nbsp;21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, which involve substantial risks and uncertainties. All statements, other than statements of
historical fact, contained in this prospectus or the information incorporated by reference in this prospectus, including statements regarding our strategy, future operations, future financial position, future revenues and profitability, projected
costs, prospects, plans and objectives of management, are forward-looking statements. The words &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;may,&#148; &#147;might,&#148;
&#147;plan,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;project,&#148; &#147;should,&#148; &#147;target,&#148; &#147;would,&#148; &#147;could,&#148; &#147;continue&#148; and similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain these identifying words. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The forward-looking statements in this prospectus and the
information incorporated by reference herein include, among other things, statements about: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of the <FONT STYLE="white-space:nowrap">COVID-19</FONT> pandemic on our clinical trials, business and
operations and our response to the pandemic; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ongoing clinical trials, including our PRISM trial of Haduvio (nalbuphine ER) for the treatment of pruritus
associated with prurigo nodularis; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our plans to develop and, if approved, subsequently commercialize Haduvio for the treatment of pruritus
associated with prurigo nodularis or for other serious neurologically mediated conditions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding the timing for the initiation of clinical trials and the reporting of data from such
trials; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the timing of and our ability to submit applications for, and to obtain and maintain regulatory approvals for
Haduvio; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our expectations regarding our ability to fund our operating expenses and capital expenditure requirements with
our cash and cash equivalents and to continue as a going concern; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our estimates regarding expenses, future revenue, timing of any future revenue, capital requirements and needs
for additional financing; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of government laws and regulations; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our competitive position; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to establish and maintain collaborations or obtain additional funding. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our
forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included,
or incorporated by reference, in this prospectus, particularly in the &#147;Risk Factors&#148; section of this prospectus and in the sections captioned &#147;Risk Factors&#148; in our most recent Annual Report on Form
<FONT STYLE="white-space:nowrap">10-K,</FONT> our most recent Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> and other filings we make with the Securities and Exchange Commission, or SEC, from time to time, which are
incorporated by reference herein in their entirety, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any
future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You should read this
prospectus, the documents incorporated by reference in herein and the documents that we have filed as exhibits to the registration statement of which this prospectus is a part completely and with the understanding that our actual future results may
be materially different from what we expect. The forward-looking statements contained in this prospectus and incorporated by reference herein are made as of the date hereof, and we do not assume any obligation to update any forward-looking
statements except as required by applicable law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the shares of common stock that may be offered and sold from time to time by Lincoln Park. We are not selling any securities under
this prospectus and we will not receive any proceeds from the sale of shares by Lincoln Park. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, we may receive up to $15.0&nbsp;million in
aggregate gross proceeds under the Purchase Agreement from any sales of common stock we make to Lincoln Park pursuant to the Purchase Agreement after the date of prospectus. Any proceeds we receive from our sale of shares of common stock to Lincoln
Park under the Purchase Agreement will be used for general corporate purposes, which may include funding our clinical trials, working capital and capital expenditures, and repayment of our debt. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may temporarily invest the net proceeds in investment-grade, interest-bearing securities until they are used for their stated purpose. We have not
determined the amount of net proceeds to be used specifically for such purposes. As a result, management will retain broad discretion over the allocation of any proceeds from the sale of any shares of our common stock under the Purchase Agreement.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_7"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The sale of shares of our common stock to Lincoln Park pursuant to the Purchase Agreement will have a dilutive impact on our stockholders. In addition, the
lower the price of our common stock is at the time we exercise our right to sell shares to Lincoln Park, the more shares of common stock we will have to issue to Lincoln Park pursuant to the Purchase Agreement and the more dilution our existing
stockholders will experience. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our net tangible book value as of March&nbsp;31, 2021 was approximately $23.7&nbsp;million, or $1.19 per share. Net
tangible book value per share is determined by dividing our total tangible assets, less total liabilities, by the number of shares of common stock outstanding as of March&nbsp;31, 2021. Dilution with respect to net tangible book value per share
represents the difference between the amount per share paid by Lincoln Park to us pursuant to the Purchase Agreement and the net tangible book value per share of common stock immediately after such issuances to Lincoln Park. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After giving effect to the issuance of 170,088 shares of our common stock as the Commitment Shares and assuming the sale of 5,000,000 shares of our common
stock as Purchase Shares to Lincoln Park pursuant to the Purchase Agreement at an assumed average sale price of $2.18 per share, the last reported sale price of our common stock on the Nasdaq Global Select Market on July&nbsp;6, 2021, and after
deducting estimated offering expenses payable by us, our as adjusted net tangible book value as of March&nbsp;31, 2021 would have been approximately $34.5 million, or $1.37 per share. This represents an immediate increase in net tangible book value
of $0.19 per share to existing stockholders and dilution of $0.81 per share of as adjusted net tangible book value to investors based on the assumed average sale price of $2.18 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To the extent that stock options outstanding as of March&nbsp;31, 2021 have been or may be exercised or other shares are issued at prices below the prices
paid by investors purchasing shares of our common stock in this offering, investors in this offering may experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if
we believe we have sufficient funds for our current or future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further
dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_8"></A>THE LINCOLN PARK TRANSACTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2021, we and Lincoln Park
entered into the Purchase Agreement and the Registration Rights Agreement. The Purchase Agreement provides that, subject to the terms and conditions set forth therein, we may sell to Lincoln Park up to $15.0&nbsp;million of shares of common stock
from time to time during the term of the Purchase Agreement. Pursuant to the terms of the Registration Rights Agreement, we have filed the registration statement of which this prospectus is a part to register for resale under the Securities Act the
shares that have been or may be issued to Lincoln Park under the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Purchase Agreement, on June&nbsp;18,
2021 we issued 170,088 shares of our common stock to Lincoln Park as commitment shares, or the Commitment Shares, as consideration for Lincoln Park&#146;s commitment to purchase shares of our common stock under the Purchase Agreement. The Commitment
Shares are included in the 5,170,088 shares of common stock being registered under the registration statement of which this prospectus is a part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under
the terms and subject to the conditions of the Purchase Agreement, we have the right, but not the obligation, to sell to Lincoln Park, and Lincoln Park is obligated to purchase from us, up to $15.0&nbsp;million of shares of our common stock. Such
sales of common stock by us, if any, will be subject to certain limitations, and may occur from time to time, at our sole discretion, over a <FONT STYLE="white-space:nowrap">24-month</FONT> period commencing on the date that the registration
statement of which this prospectus is a part is declared effective by the SEC and a final prospectus in connection therewith is filed and the other conditions set forth in the Purchase Agreement are satisfied. Lincoln Park has no right to require us
to sell any shares of common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as we direct, subject to conditions set forth in the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the Purchase Agreement provides that we may sell up to $15.0&nbsp;million of our common stock to Lincoln Park, only 5,170,088 of the shares of common
stock that have been or may be issued to Lincoln Park are being offered under this prospectus. Depending on the market prices of our common stock at the times we elect to issue and sell shares to Lincoln Park under the Purchase Agreement, in
accordance with the terms of the Registration Rights Agreement, we may need to register for resale under the Securities Act additional shares of our common stock in order to receive aggregate gross proceeds equal to the $15.0&nbsp;million total
commitment available to us under the Purchase Agreement. If we elect to issue and sell more than the 5,170,088 shares offered under this prospectus to Lincoln Park, which we have the right, but not the obligation, to do, we must first register for
resale under the Securities Act any such additional shares, which could cause additional substantial dilution to our stockholders. The number of shares ultimately offered for resale by Lincoln Park is dependent upon the number of shares we sell to
Lincoln Park under the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under applicable rules of Nasdaq and pursuant to the terms of the Purchase Agreement, in no event may we issue
or sell to Lincoln Park under the Purchase Agreement shares of our common stock in excess of 4,175,167 shares (including the Commitment Shares), which represents 19.99% of the 20,886,283 shares of our common stock that were outstanding immediately
prior to the execution of the Purchase Agreement, or the Exchange Cap, unless (i)&nbsp;we obtain stockholder approval to issue shares of our common stock in excess of the Exchange Cap or (ii)&nbsp;the average price of all applicable sales of our
common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.18 per share (which represents the closing sale price of our common stock immediately prior to the execution of the Purchase Agreement), such that the issuances and sales
of our common stock to Lincoln Park under the Purchase Agreement would be exempt from the Exchange Cap limitation under applicable Nasdaq rules. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
Purchase Agreement also prohibits us from directing Lincoln Park to purchase any shares of our common stock if those shares, when aggregated with all other shares of common stock then beneficially owned by Lincoln Park and its affiliates, would
result in Lincoln Park and its affiliates having beneficial ownership, at any single point in time, of more than 9.99% of the then total outstanding shares of common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Purchase of Shares under the Purchase Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Regular Purchases </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Purchase Agreement, we
may from time to time, at our discretion, direct Lincoln Park to purchase on any single business day, which we refer to as a &#147;Regular Purchase,&#148; up to (i) 100,000 shares of common stock if the closing sale price of our common stock is at
least $7.50 per share on Nasdaq, (ii) 75,000 shares of common stock if the closing sale price of our common stock is at least $5.00 per share on Nasdaq or (iii) 50,000 shares of common stock if the closing sale price of our common stock is below
$5.00 per share on Nasdaq. In any case, Lincoln Park&#146;s commitment in any single Regular Purchase may not exceed $2,000,000. The foregoing share amounts and per share prices will be adjusted for any reorganization, recapitalization, <FONT
STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction occurring after the date of the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for each such Regular Purchase will be equal to the lower of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the lowest sale price for our common stock on Nasdaq on the purchase date of such shares; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the average of the three lowest closing sale prices for our common stock on Nasdaq during the 10 consecutive
business days ending on the business day immediately preceding the purchase date of such shares. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Accelerated Purchases
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also direct Lincoln Park, on any business day on which we have properly submitted a Regular Purchase notice for the maximum number of
shares of our common stock that we are then permitted to include in a single Regular Purchase notice, to purchase an additional amount of our common stock, which we refer to as an Accelerated Purchase, not to exceed the lesser of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">three times the number of shares purchased pursuant to such corresponding Regular Purchase; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">30% of the aggregate shares of our common stock traded on Nasdaq during all or, if certain trading volume or
market price thresholds specified in the Purchase Agreement are crossed on the applicable Accelerated Purchase date, which is defined as the next business day following the purchase date for the corresponding Regular Purchase, the portion of the
normal trading hours on the applicable Accelerated Purchase date prior to such time that any one of such thresholds is crossed, which period of time on the applicable Accelerated Purchase date we refer to as the &#147;Accelerated Purchase
Measurement Period&#148;. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for each such Accelerated Purchase will be equal to 97% of the lower of: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volume-weighted average price of our common stock on Nasdaq during the applicable Accelerated Purchase
Measurement Period on the applicable Accelerated Purchase date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the closing sale price of our common stock on Nasdaq on the applicable Accelerated Purchase date.
</P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Additional Accelerated Purchases </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may also direct Lincoln Park on any business day on which an Accelerated Purchase has been completed and all of the shares to be purchased thereunder (and
under the corresponding Regular Purchase) have been properly delivered to Lincoln Park in accordance with the Purchase Agreement prior to such time on such business day to purchase an additional amount of our common stock, which we refer to as an
Additional Accelerated Purchase, of up to the lower of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">three times the number of shares purchased pursuant to the applicable corresponding Regular Purchase; and
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">30% of the aggregate shares of our common stock traded on Nasdaq during a certain portion of the normal trading
hours on the applicable Additional Accelerated Purchase date as determined in </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
accordance with the Purchase Agreement, which period of time on the applicable Additional Accelerated Purchase date we refer to as the Additional Accelerated Purchase Measurement Period.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may, in our sole discretion, submit multiple Additional Accelerated Purchase notices to Lincoln Park on a single Accelerated
Purchase date, provided that all prior Accelerated Purchases and Additional Accelerated Purchases (including those that have occurred earlier on the same day) have been completed and all of the shares to be purchased thereunder (and under the
corresponding Regular Purchase) have been properly delivered to Lincoln Park in accordance with the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share for
each such Additional Accelerated Purchase will be equal to 97% of the lower of: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volume-weighted average price of our common stock on Nasdaq during the applicable Additional Accelerated
Purchase Measurement Period on the applicable Additional Accelerated Purchase date; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the closing sale price of our common stock on Nasdaq on the applicable Additional Accelerated Purchase date.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the case of Regular Purchases, Accelerated Purchases and Additional Accelerated Purchases, the purchase price per share will be
equitably adjusted for any reorganization, recapitalization, <FONT STYLE="white-space:nowrap">non-cash</FONT> dividend, stock split, reverse stock split or other similar transaction occurring during the business days used to compute the purchase
price. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Other than as described above, there are no trading volume requirements or restrictions under the Purchase Agreement, and we will control the
timing and amount of any sales of our common stock to Lincoln Park. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Minimum Share Price </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Purchase Agreement, we may not effect any sales of our common stock on any purchase date that the closing sale price of our common stock is less than
the floor price of $0.50 per share of common stock, subject to adjustment. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Events of default under the Purchase Agreement include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effectiveness of the registration statement of which this prospectus forms a part lapses for any reason
(including, without limitation, the issuance of a stop order), or any required prospectus supplement and accompanying prospectus are unavailable for the resale by Lincoln Park of our common stock offered hereby, and such lapse or unavailability
continues for a period of 10 consecutive business days or for more than an aggregate of 30 business days in any <FONT STYLE="white-space:nowrap">365-day</FONT> period, but excluding a lapse or unavailability where (i)&nbsp;we terminate a
registration statement after Lincoln Park has confirmed in writing that all of the shares of our common stock covered thereby have been resold or (ii)&nbsp;we supersede one registration statement with another registration statement, including
(without limitation) by terminating a prior registration statement when it is effectively replaced with a new registration statement covering the shares of our common stock covered by the Purchase Agreement (provided in the case of this clause
(ii)&nbsp;that all of the shares of our common stock covered by the superseded (or terminated) registration statement that have not theretofore been resold are included in the superseding (or new) registration statement); </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">suspension by the principal market of our common stock from trading for a period of one business day;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the delisting of our common stock from the Nasdaq Global Select Market, our principal market, provided that our
common stock is not immediately thereafter trading on the Nasdaq Global Market, </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
the Nasdaq Capital Market, the New York Stock Exchange, the NYSE Arca, the NYSE American, the OTC Bulletin Board or the OTC Markets Group, Inc. (or any nationally recognized successor to any of
the foregoing); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the failure for any reason by our transfer agent to issue shares of our common stock to Lincoln Park by the
second business day after any Regular Purchase date, Accelerated Purchase date or Additional Accelerated Purchase date, as applicable, on which Lincoln Park is entitled to receive such shares; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our breach of any representation, warranty, covenant or other term or condition contained in the Purchase
Agreement or Registration Rights Agreement that has or could have a material adverse effect on us and, in the case of a breach of a covenant that is reasonably curable, that is not cured within five business days; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">any voluntary or involuntary participation or threatened participation in insolvency or bankruptcy proceedings by
or against us; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if at any time we are not eligible to transfer our common stock electronically via the DWAC system; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if at any time the Exchange Cap is reached and our stockholders have not approved the transactions contemplated
by the Purchase Agreement in accordance with the applicable Nasdaq rules, to the extent applicable. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park does not have the
right to terminate the Purchase Agreement upon any of the events of default set forth above, however, the Purchase Agreement will automatically terminate upon initiation of insolvency or bankruptcy proceedings by or against us. During an event of
default, all of which are outside of Lincoln Park&#146;s control, we may not direct Lincoln Park to purchase any shares of our common stock under the Purchase Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Our Termination Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have the unconditional right,
at any time, for any reason and without any payment or liability to us, to give notice to Lincoln Park to terminate the Purchase Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No
Short-Selling or Hedging by Lincoln Park </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park has agreed that neither it nor any of its affiliates shall engage in any direct or indirect
short-selling or hedging of our common stock during any time prior to the termination of the Purchase Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Prohibitions on Similar Financings
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Subject to specified exceptions included in the Purchase Agreement, we are limited in our ability to enter into any new &#147;equity line&#148; or
similar transaction whereby an investor is irrevocably bound to purchase securities over a period of time from us at a price based on the market price of our common stock at the time of such purchase. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Effect of Performance of the Purchase Agreement on our Stockholders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All shares registered for resale in this offering that have been or may be issued or sold by us to Lincoln Park under the Purchase Agreement are expected to be
freely tradable. The sale by Lincoln Park of a significant amount of shares registered for resale in this offering at any given time could cause the market price of our common stock to decline and to be highly volatile. Sales of our common stock to
Lincoln Park, if any, will depend upon market conditions and other factors to be determined by us. We may ultimately decide to sell to Lincoln Park all, some or none of the additional shares of our common stock that may be available for us to sell
pursuant to the Purchase Agreement. If and when we do sell shares to Lincoln Park, after Lincoln Park has acquired the shares, Lincoln Park may resell all, some or none of those shares at any time or from time to time in
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
its discretion. Therefore, sales to Lincoln Park by us under the Purchase Agreement may result in substantial dilution to the interests of other holders of our common stock. In addition, if we
sell a substantial number of shares to Lincoln Park under the Purchase Agreement, or if investors expect that we will do so, the actual sales of shares or the mere existence of our arrangement with Lincoln Park may make it more difficult for us to
sell equity or equity-related securities in the future at a time and at a price that we might otherwise wish to effect such sales. However, we have the right to control the timing and amount of any additional sales of our shares to Lincoln Park and
the Purchase Agreement may be terminated by us at any time at our discretion without any cost to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Purchase Agreement and
as of the date hereof, we have the right, but not the obligation, to direct Lincoln Park to purchase from us up to $15.0&nbsp;million of our common stock. Depending on the price per share at which we sell our common stock to Lincoln Park pursuant to
the Purchase Agreement, we may need to sell to Lincoln Park under the Purchase Agreement more shares of our common stock than are offered under this prospectus in order to receive aggregate gross proceeds equal to the $15.0&nbsp;million total
commitment available to us under the Purchase Agreement. If we choose to do so, we must first register for resale under the Securities Act such additional shares of our common stock, which could cause additional substantial dilution to our
stockholders. The number of shares ultimately offered for resale by Lincoln Park under this prospectus is dependent upon the number of shares we direct Lincoln Park to purchase under the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the amount of gross proceeds we would receive from Lincoln Park from our sale to Lincoln Park under the Purchase Agreement of
shares that may be offered by Lincoln Park for resale pursuant to this prospectus at varying purchase prices: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="16%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Assumed&nbsp;Average<BR>Purchase&nbsp;Price&nbsp;Per&nbsp;Purchase&nbsp;Share</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number of Shares&nbsp;to&nbsp;be<BR>Issued&nbsp;if&nbsp;Full&nbsp;Purchase&nbsp;(1)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage&nbsp;of<BR>Outstanding&nbsp;Shares After<BR>Giving&nbsp;Effect&nbsp;to&nbsp;the&nbsp;Issuance<BR>to Lincoln Park (2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Gross&nbsp;Proceeds&nbsp;from&nbsp;the&nbsp;Sale<BR>Shares&nbsp;to&nbsp;Lincoln&nbsp;Park&nbsp;Under<BR>the Purchase Agreement</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$0.50</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,175,167</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">2,087,584</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$1.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,175,167</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,175,167</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$1.50</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,175,167</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;6,262,751</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$2.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,175,167</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.2</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">8,350,334</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$2.18 (4)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">10,900,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$2.50</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">12,500,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$3.00</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">18.8</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">$3.50</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4,285,714</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">16.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">14,999,999</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Although the Purchase Agreement provides that we may sell up to $15.0&nbsp;million of our common stock to
Lincoln Park, we are only registering 5,170,088 shares under this prospectus which represents: (i) 170,088 shares issued as Commitment Shares and (ii)&nbsp;an additional 5,000,000 shares which may be issued to Lincoln Park in the future under the
Purchase Agreement, if and when we sell shares to Lincoln Park under the Purchase Agreement. This number of shares of common stock may or may not cover all the shares we ultimately sell to Lincoln Park under the Purchase Agreement, depending on the
purchase price per share. As a result, we have included in this column only those shares that we are registering for resale in this offering, while giving effect to the Exchange Cap and without regard to the Beneficial Ownership Cap.
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The denominator is based on 21,567,654 shares outstanding as of July&nbsp;2, 2021, which includes the
Commitment Shares issued to Lincoln Park that are offered by this prospectus, plus&nbsp;the number of shares set forth in the adjacent column that we would have sold to Lincoln Park, assuming the average purchase price in the first column. The
numerator is based on the number of shares issuable under the Purchase Agreement at the corresponding assumed average purchase price set forth in the first column. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">This number of shares reflects the Exchange Cap. We may only issue shares of our common stock in excess of the
Exchange Cap if we obtain stockholder approval to do so, or if the average price of all applicable sales of our common stock to Lincoln Park under the Purchase Agreement equals or exceeds $2.18 per share. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The closing sale price of our common stock on Nasdaq on July&nbsp;6, 2021. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_9"></A>THE SELLING STOCKHOLDER </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus relates to the possible resale by the selling stockholder, Lincoln Park, of shares of our common stock that have been or may be issued to
Lincoln Park pursuant to the Purchase Agreement. We are filing the registration statement of which this prospectus is a part pursuant to the provisions of the Registration Rights Agreement, which we entered into with Lincoln Park on June&nbsp;18,
2021 concurrently with our execution of the Purchase Agreement, in which we agreed to provide certain registration rights with respect to sales by Lincoln Park of the shares of our common stock that have been or may be issued to Lincoln Park under
the Purchase Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park, as the selling stockholder, may, from time to time, offer and sell pursuant to this prospectus up to 5,170,088
shares of our common stock that we have issued or may issue to Lincoln Park under the Purchase Agreement. The selling stockholder may sell some, all or none of the shares of common stock. We do not know how long the selling stockholder will hold the
shares of our common stock before selling them, and we currently have no agreements, arrangements or understandings with the selling stockholder regarding the sale of any of the shares of common stock. See &#147;Plan of Distribution.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table below sets forth, to our knowledge, information concerning the beneficial ownership of shares of our common stock by the selling stockholder as of
June&nbsp;18, 2021. The percentages of shares owned before and after the offering are based on 21,567,654 shares of common stock outstanding as of July&nbsp;2, 2021, which includes the Commitment Shares issued to Lincoln Park that are offered by
this prospectus. The information in the table below with respect to the selling stockholder has been obtained from the selling stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Beneficial
ownership is determined in accordance with the rules of the SEC and includes voting or investment power with respect to shares. Unless otherwise indicated below, to our knowledge, all persons named in the table have sole voting and investment power
with respect to their shares of common stock. The inclusion of any shares in this table does not constitute an admission of beneficial ownership for the person named below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Throughout this prospectus, when we refer to the shares of common stock being offered by this prospectus on behalf of the selling stockholder, we are
referring to the shares of common stock sold pursuant to the Purchase Agreement unless otherwise indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>

<TD WIDTH="40%"></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>

<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Name of Selling Stockholder</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares&nbsp;Beneficially&nbsp;Owned<BR>Prior to Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Shares<BR>Beneficially<BR>Owned<BR>Prior to<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Shares to<BR>be&nbsp;Sold&nbsp;in&nbsp;this&nbsp;Offering<BR>Assuming&nbsp;We Issue the<BR>Maximum Number of<BR>Shares Under the<BR>Purchase<BR>Agreement
(2)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Percentage<BR>of Shares<BR>to be<BR>Beneficially<BR>Owned<BR>After<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lincoln Park Capital Fund, LLC (1)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,075,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">4.98</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,170,088</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">3.41</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Josh Scheinfeld and Jonathan Cope, the Managing Members of Lincoln Park Capital, LLC, are deemed to be
beneficial owners of all of the shares of common stock owned by Lincoln Park Capital Fund, LLC. Messrs. Cope and Scheinfeld have shared voting and investment power over the shares being offered under this prospectus. Lincoln Park Capital, LLC is not
a licensed broker dealer or an affiliate of a licensed broker dealer. The address of Lincoln Park Capital Fund, LLC is 440 North Wells, Suite 410, Chicago, Illinois 60654. </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Although the Purchase Agreement provides that we may sell up to $15.0&nbsp;million of our common stock to
Lincoln Park, only 5,170,088 of the shares of common stock that have been or may be issued to Lincoln Park are being offered under this prospectus which represents: (i) 170,088 shares issued as Commitment Shares and (iii)&nbsp;an aggregate of
5,000,000 shares that may be sold by us to Lincoln Park at our discretion from time to time over a <FONT STYLE="white-space:nowrap">24-month</FONT> period commencing after the satisfaction of certain conditions set forth in the Purchase Agreement.
Depending on the price per share at which we sell our common stock to Lincoln Park pursuant to the Purchase Agreement, we may need to sell to Lincoln Park under the Purchase </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
Agreement more shares of our common stock than are offered under this prospectus in order to receive aggregate gross proceeds equal to the full $15.0&nbsp;million available to us under the
Purchase Agreement. If we choose to do so, we must first register for resale under the Securities Act such additional shares. The number of shares ultimately offered for resale by Lincoln Park is dependent upon the number of shares we sell to
Lincoln Park under the Purchase Agreement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_10"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This
description is based upon, and is qualified by reference to, our certificate of incorporation, our <FONT STYLE="white-space:nowrap">by-laws</FONT> and applicable provisions of Delaware corporate law. You should read our certificate of incorporation
and <FONT STYLE="white-space:nowrap">by-laws,</FONT> which are filed as exhibits to the registration statement of which this prospectus forms a part, for the provisions that are important to you. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our authorized capital stock consists of 200,000,000 shares of common stock and 5,000,000 shares of preferred stock. As of July&nbsp;2, 2021, 21,567,654
shares of common stock were outstanding and no shares of preferred stock were outstanding. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Annual Meeting.</I><B> </B>Annual meetings of our stockholders are held on the date designated in accordance with our
<FONT STYLE="white-space:nowrap">by-laws.</FONT> Written notice must be mailed to each stockholder entitled to vote not less than ten nor more than 60 days before the date of the meeting. The presence in person or by proxy of the holders of record
of a majority in voting power of our issued and outstanding shares entitled to vote at such meeting constitutes a quorum for the transaction of business at meetings of the stockholders. Special meetings of the stockholders may be called for any
purpose by the board of directors and shall be called by the chairman of the board or the secretary upon the written request, stating the purpose of such meeting, of the holders of a majority of the outstanding shares of all classes of capital stock
entitled to vote at the meeting. Except as may be otherwise provided by applicable law, our certificate of incorporation or our <FONT STYLE="white-space:nowrap">by-laws,</FONT> all elections shall be decided by a plurality, and all other questions
shall be decided by a majority of the votes cast by stockholders entitled to vote thereon at a duly held meeting of stockholders at which a quorum is present. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Voting Rights. </I>Each holder of common stock is entitled to one vote for each share held of record on all matters to be voted upon by stockholders. The
common stock does not have cumulative voting rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Dividends</I>. Subject to the rights, powers and preferences of any outstanding preferred stock,
and except as provided by law or in our certificate of incorporation, dividends may be declared and paid or set aside for payment on the common stock out of legally available assets or funds when and as declared by the board of directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Liquidation, Dissolution and Winding Up</I>. In the event of our liquidation or dissolution, the holders of our common stock are entitled to receive
proportionately all assets available for distribution to stockholders after the payment of all debts and other liabilities and subject to the prior rights of any outstanding preferred stock. The rights, preferences and privileges of holders of our
common stock are subject to and may be adversely affected by the rights of the holders of shares of any series of our preferred stock that we may designate and issue in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Other Rights</I>. Holders of the common stock have no right to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">convert the stock into any other security; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">have the stock redeemed; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchase additional stock; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">maintain their proportionate ownership interest. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Holders of shares of the common stock are not required to make additional capital contributions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Transfer Agent and Registrar</I>. Computershare Trust Company, N.A. is transfer agent and registrar for
the common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exchange Listing</I>. Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TRVI.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are authorized to issue &#147;blank
check&#148; preferred stock, which may be issued in one or more series upon authorization of our board of directors. Our board of directors is authorized to fix the designations, powers, preferences and the relative, participating, optional or other
special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The authorized shares of our preferred stock are available for issuance without further action by our stockholders, unless such
action is required by applicable law or the rules of any stock exchange on which our securities may be listed. If the approval of our stockholders is not required for the issuance of shares of our preferred stock, our board may determine not to seek
stockholder approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Provisions of Our Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-laws</FONT> and Delaware Law That May
Have Anti-Takeover Effects </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Board of Directors</I>. Our certificate of incorporation and <FONT STYLE="white-space:nowrap">by-laws</FONT> provide for
a board of directors divided as nearly equally as possible into three classes. Each class is elected to a term expiring at the annual meeting of stockholders held in the third year following the year of such election. The number of directors
comprising our board of directors is fixed from time to time by the board of directors. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors by Stockholders</I>. Delaware law
provides that members of our board of directors may only be removed for cause by a vote of the holders of 75% of the outstanding shares entitled to vote on the election of the directors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Stockholder Nomination of Directors</I>. Our <FONT STYLE="white-space:nowrap">by-laws</FONT> provide that a stockholder must notify us in writing of any
stockholder nomination of a director not more than 120 days and not less than the 90 days prior to the first anniversary of the preceding year&#146;s annual meeting; provided, that if the date of the annual meeting is advanced or delayed by more
than 30 days from such anniversary date, notice by the stockholder to be timely must be so delivered not earlier than the 120th day prior to the date of such annual meeting and not later than the close of business on the later of (x)&nbsp;the 90th
day prior to the date of such meeting and (y)&nbsp;the 10th day following the day on which notice of the date of such annual meeting was mailed or public disclosure of the date of such annual meeting was made, whichever occurs first. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>No Action By Written Consent</I>. Our certificate of incorporation provides that our stockholders may not act by written consent and may only act at duly
called meetings of stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Delaware Law</I>. We are subject to Section&nbsp;203 of the Delaware General Corporation Law, or the DGCL. Subject to
certain exceptions, Section&nbsp;203 prevents a publicly held Delaware corporation from engaging in a &#147;business combination&#148; with any &#147;interested stockholder&#148; for three years following the date that the person became an
interested stockholder, unless either the interested stockholder attained such status with the approval of our board of directors, the business combination is approved by our board of directors and stockholders in a prescribed manner or the
interested stockholder acquired at least 85% of our outstanding voting stock in the transaction in which it became an interested stockholder. A &#147;business combination&#148; includes, among other things, a merger or consolidation involving us and
the &#147;interested stockholder&#148; and the sale of more than 10% of our assets. In general, an &#147;interested stockholder&#148; is any entity or person beneficially owning 15% or more of our outstanding voting stock and any entity or person
affiliated with or controlling or controlled by such entity or person. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Exclusive Forum Selection</I>. Our certificate of incorporation provides that,
unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware (or, if the Court of Chancery of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the State of Delaware does not have jurisdiction, the federal district court for the District of Delaware) shall be the sole and exclusive forum for (1)&nbsp;any derivative action or proceeding
brought on behalf of our company, (2)&nbsp;any action asserting a claim of breach of a fiduciary duty owed by any of our directors, officers, other employees or stockholders to our company or our stockholders, (3)&nbsp;any action asserting a claim
arising pursuant to any provision of the DGCL or as to which the DGCL confers jurisdiction on the Court of Chancery of the State of Delaware or (4)&nbsp;any action asserting a claim arising pursuant to any provision of our certificate of
incorporation or <FONT STYLE="white-space:nowrap">by-laws</FONT> (in each case, as they may be amended from time to time) or governed by the internal affairs doctrine. Our certificate of incorporation further provides that, unless we consent in
writing to the selection of an alternative forum, the federal district courts of the United States of America shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of
action arising under the Securities Act. Neither of these choice of forum provisions would affect suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder, jurisdiction over which is
exclusively vested by statute in the United States federal courts, or any other claim for which United States federal courts have exclusive jurisdiction. Although our certificate of incorporation contains the choice of forum provisions described
above, it is possible that a court could rule that such provisions are inapplicable for a particular claim or action. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are party to a second amended and restated investors&#146; rights agreement, which we refer to as the investors&#146; rights agreement, under which holders
of a total of 7,826,515 shares of our common stock have the right to require us to register these shares under the Securities Act under specified circumstances. We refer to the shares with these registration rights as registrable securities. After
registration pursuant to these rights, the registrable securities will become freely tradable without restriction under the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Demand and
Form <FONT STYLE="white-space:nowrap">S-3</FONT> Registration Rights.</I><B> </B>Subject to specified limitations and conditions set forth in the investors&#146; rights agreement, at any time, the holders of at least a majority of the then
outstanding registrable securities may demand that we register registrable securities then outstanding under the Securities Act for purposes of a public offering having an aggregate offering price to the public of not less than $10.0&nbsp;million,
net of certain expenses, underwriting discounts and selling commissions. We are not obligated to file a registration statement pursuant to this provision on more than two occasions. In addition, subject to specified limitations and conditions set
forth in the investors&#146; rights agreement, at any time when we are eligible to file a registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> holders of the registrable securities then outstanding may request that we register
their registrable securities on Form <FONT STYLE="white-space:nowrap">S-3</FONT> for purposes of a public offering for which the reasonably anticipated aggregate offering price to the public, net of certain expenses, underwriting discounts and
selling commissions, would exceed $1.0&nbsp;million. We are not obligated to file a registration statement pursuant to this provision on more than two occasions in any <FONT STYLE="white-space:nowrap">12-month</FONT> period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Incidental Registration Rights.</I> If we propose to register for our own account or for the account of our other stockholders any of our common stock
under the Securities Act, the holders of registrable securities will be entitled to notice of the registration and, subject to specified exceptions, have the right to require us to register all or a portion of the registrable securities then held by
them in that registration. In the event that any registration in which the holders of registrable securities participate pursuant to our investors&#146; rights agreement is an underwritten public offering, we have agreed to enter into an
underwriting agreement in usual and customary form and use our commercially reasonable efforts to facilitate such offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Expenses and
Indemnification.</I> Pursuant to the investors&#146; rights agreement, we are required to pay all registration expenses, including all registration and filing fees, exchange listing fees, printing expenses, fees and expenses of one counsel selected
by the selling stockholders to represent the selling stockholders, state Blue Sky fees and expenses, and the expense of any special audits incident to or required by any such registration, but excluding underwriting discounts, selling commissions,
stock transfer taxes and the fees and expenses of the selling stockholders&#146; own counsel (other than the counsel selected to represent all selling stockholders). The investors&#146; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
rights agreement contains customary cross-indemnification provisions, pursuant to which we are obligated to indemnify the selling stockholders in the event of material misstatements or alleged
material misstatements or material omissions or alleged material omissions in the registration statement attributable to us, or any violation or alleged violation, whether by action or inaction, by us under the Securities Act; the Exchange Act; any
state securities or Blue Sky law or any rule or regulation promulgated under the Securities Act, the Exchange Act or any state securities or Blue Sky law in connection with such registration statement or the qualification or compliance of the
offering, and they are obligated to indemnify us for material misstatements or omissions in the registration statement attributable to them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition,
in connection with a private placement to New Enterprise Associates, or NEA, in May 2019, we granted NEA the right to require us to register under the Securities Act under specified circumstances the shares issued to NEA in such private placement,
and upon such registration, such shares would become freely tradable without restriction under the Securities Act. Furthermore, in connection with entering into the Purchase Agreement, we and Lincoln Park entered into the Registration Rights
Agreement, pursuant to the term of which we have filed the registration statement of which this prospectus is a part to register for resale under the Securities Act the shares that have been or may be issued to Lincoln Park under the Purchase
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares of common stock offered by this prospectus are being offered by the selling stockholder, Lincoln Park. The selling stockholder may sell all or a
portion of the shares of common stock offered hereby from time to time directly to purchasers or through one or more underwriters, broker-dealers or agents, at market prices prevailing at the time of sale, at prices related to such market prices, at
a fixed price or prices subject to change or at negotiated prices, by a variety of methods including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">on any national securities exchange or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on which the common stock may be listed or quoted at the time of sale; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">block trades in which a broker-dealer may attempt to sell the shares as agent but may position and resell a
portion of the block as principal to facilitate the transaction; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">purchases by a broker-dealer, as principal, and a subsequent resale by the broker-dealer for its account;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in &#147;at the market&#148; offerings to or through market makers into an existing market for the common stock;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">an exchange distribution in accordance with the rules of the applicable exchange; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">privately negotiated transactions; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">in transactions otherwise than on such exchanges or in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through a combination of any such methods; or </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">through any other method permitted under applicable law. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We will pay the expenses incident to the registration and offering of the shares of common stock offered hereby. We have agreed to indemnify Lincoln Park and
certain other persons against certain liabilities in connection with the offering of the shares of common stock offered hereby, including liabilities arising under the Securities Act or, if such indemnity is unavailable, to contribute amounts
required to be paid in respect of such liabilities. Lincoln Park has agreed to indemnify us against liabilities under the Securities Act that may arise from certain written information furnished to us by Lincoln Park specifically for use in this
prospectus or, if such indemnity is unavailable, to contribute amounts required to be paid in respect of such liabilities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park is an
&#147;underwriter&#148; within the meaning of Section&nbsp;2(a)(11) of the Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In effecting sales, brokers-dealers engaged by the selling
stockholder may arrange for other brokers-dealers to participate. If the selling stockholder effects such transactions by selling shares of common stock to or through underwriters, broker-dealers or agents, such underwriters, broker-dealers or
agents may receive commissions in the form of discounts, concessions or commissions from the selling stockholder or commissions from purchasers of common stock for whom they may act as agent or to whom they may sell as principal. Underwriters may
sell securities to or through dealers, and dealers may receive compensation in the form of discounts, concessions or commissions from the underwriters and/or commissions from the purchasers for whom they may act as agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Any underwriters, brokers, dealers or agents that participate in such distribution may be deemed to be &#147;underwriters&#148; within the meaning of the
Securities Act, and any discounts, commissions or concessions received by any underwriters, brokers, dealers or agents might be deemed to be underwriting discounts and commissions under the Securities Act. Any selling stockholder who is an
&#147;underwriter&#148; within the meaning of the Securities Act will be subject to the prospectus delivery requirements of the Securities Act and the provisions of the Exchange Act and the rules thereunder relating to stock manipulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We know of no existing arrangements between Lincoln Park or any other stockholder, broker, dealer, underwriter or agent relating to the sale or distribution
of the shares offered by this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Lincoln Park has represented to us that at no time prior to the Purchase Agreement has Lincoln Park or its
agents, representatives or affiliates engaged in or effected, in any manner whatsoever, directly or indirectly, any short sale (as such term is defined in Rule 200 of Regulation SHO of the Exchange Act) of our common stock or any hedging
transaction, which establishes a net short position with respect to our common stock. Lincoln Park agreed that during the term of the Purchase Agreement, it, its agents, representatives or affiliates will not enter into or effect, directly or
indirectly, any of the foregoing transactions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have advised Lincoln Park that it is required to comply with Regulation M promulgated under the
Exchange Act. With certain exceptions, Regulation M precludes the selling stockholder, any affiliated purchasers, and any broker-dealer or other person who participates in the distribution from bidding for or purchasing, or attempting to induce any
person to bid for or purchase any security which is the subject of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize the price of a security in connection with
the distribution of that security. All of the foregoing may affect the marketability of the securities offered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In order to comply
with the securities laws of some states, shares of our common stock sold in those jurisdictions may only be sold through registered or licensed brokers or dealers. In addition, in some states, shares of our common stock may not be sold unless the
shares of common stock have been registered or qualified for sale in that state or an exemption from registration or qualification is available and is complied with. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This offering will terminate (i)&nbsp;on the date that all shares of common stock issued or issuable under the Purchase Agreement offered by this prospectus
have been sold by Lincoln Park or (ii) 180 days following the earlier of (a)&nbsp;the maturity date (as set forth in the Purchase Agreement) and (b)&nbsp;the date of termination of the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TRVI&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The validity of the shares of our common stock offered hereby is being passed upon for us by Wilmer Cutler Pickering Hale and Dorr&nbsp;LLP. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements included in our Annual Report on
Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2020 as set forth in their report, which is incorporated by reference in this prospectus and elsewhere in this registration statement. Our financial statements
are incorporated by reference in reliance on Ernst&nbsp;&amp; Young LLP&#146;s report, given on their authority as experts in accounting and auditing.</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_14"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other documents with the SEC. Our SEC filings are available to the public over the
Internet at the SEC&#146;s website at http://www.sec.gov. Copies of certain information filed by us with the SEC are also available on our website at http://www.trevitherapeutics.com/. Our website is not a part of this prospectus and is not
incorporated by reference in this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement we filed with the SEC. This prospectus omits some
information contained in the registration statement in accordance with SEC rules and regulations. You should review the information and exhibits in the registration statement for further information about us and our consolidated subsidiary and the
securities we are offering. Statements in this prospectus concerning any document we filed as an exhibit to the registration statement or that we otherwise filed with the SEC are not intended to be comprehensive and are qualified by reference to
these filings. You should review the complete document to evaluate these statements. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom153682_15"></A>INCORPORATION OF
CERTAIN DOCUMENTS BY REFERENCE </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference much of the information we file with the SEC, which means that we can
disclose important information to you by referring you to those publicly available documents. The information that we incorporate by reference in this prospectus is considered to be part of this prospectus. Any statement contained in a previously
filed document incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained in this prospectus modifies or replaces that statement. This prospectus incorporates by
reference the documents listed below (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-38886)</FONT> and any future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act after the date of this prospectus and
prior to the sale of all the shares covered by this prospectus, other than the portions of those documents not deemed to be filed. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Annual Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000156459021015506/trvi-10k_20201231.htm">Form
 <FONT STYLE="white-space:nowrap">10-K</FONT></A> for the fiscal year ended December&nbsp;31, 2020, filed with the SEC on March&nbsp;25, 2021, including the information specifically incorporated by reference into such Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> from our <A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312521134252/d43806ddef14a.htm">definitive proxy statement</A> for our 2021 Annual Meeting of Stockholders filed with the SEC on
April&nbsp;27, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Quarterly Report on <A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000156459021027550/trvi-10q_20210331.htm">Form
 <FONT STYLE="white-space:nowrap">10-Q</FONT></A> for the quarterly period ended March&nbsp;31, 2021, filed with the SEC on May&nbsp;13, 2021; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on <A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312521089553/d163250d8k.htm">March
<U></U> 22, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312521105160/d163942d8k.htm">April<U></U>&nbsp;
2, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312521195073/d195500d8k.htm">June<U></U>&nbsp;
21, 2021</A>, <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1563880/000156459021033643/trvi-8k_20210616.htm">June<U></U>&nbsp;
21, 2021</A> and <A HREF="http://www.sec.gov/Archives/edgar/data/../../../ix?doc=/Archives/edgar/data/1563880/000156459021035888/trvi-8k_20210706.htm">July 7, 2021</A>; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The description of our common stock contained in our Registration Statement on <A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519124152/d643194d8a12b.htm">Form
 <FONT STYLE="white-space:nowrap">8-A</FONT></A> filed on April&nbsp;29, 2019, including any amendments or reports filed for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A statement contained in a document incorporated by reference into this prospectus shall be deemed to be modified or superseded for purposes of this
prospectus to the extent that a statement contained in this prospectus, any prospectus supplement or in any other subsequently filed document which is also incorporated in this prospectus modifies or replaces such statement. Any statements so
modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may request a copy of these
filings, at no cost, by writing or calling us at the following address or telephone number: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Trevi Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">195 Church Street, 14th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">New
Haven, Connecticut 06510 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(203) <FONT STYLE="white-space:nowrap">304-2499</FONT> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:36pt; margin-bottom:0pt; font-size:16pt; font-family:Times New Roman" ALIGN="center"><B>5,170,088 Shares </B></P>
<P STYLE="margin-top:80pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P> <P STYLE="font-size:80pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PROSPECTUS
</B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:280pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2021 </B></P>
<P STYLE="font-size:30pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P>
<P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>PART II </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INFORMATION NOT REQUIRED IN PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;13.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Other Expenses of Issuance and Distribution. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth the various expenses to be incurred in connection with the sale and distribution of the securities being registered hereby, all
of which will be borne by us (except any underwriting discounts and commissions and expenses incurred by the selling stockholder for brokerage, accounting, tax or legal services or any other expenses incurred by the selling stockholder in disposing
of the shares). All amounts shown are estimates except the SEC registration fee. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="68%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="79%"></TD>

<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Amount</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SEC registration fee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">1,218.37</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounting fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">15,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Legal fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">59,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transfer agent fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">5,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Miscellaneous fees and expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">25,781.63</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">106,000.00</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;14.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Indemnification of Directors and Officers. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;102 of the Delaware General Corporation Law, or the DGCL, permits a corporation to eliminate the personal liability of its directors to the
corporation or its stockholders for monetary damages for a breach of fiduciary duty as a director, except where the director breached his or her duty of loyalty, failed to act in good faith, engaged in intentional misconduct or knowingly violated a
law, authorized the payment of a dividend or approved a stock repurchase in violation of Delaware corporate law or obtained an improper personal benefit. Our certificate of incorporation provides that no director shall be personally liable to us or
our stockholders for monetary damages for any breach of fiduciary duty as a director, notwithstanding any provision of law imposing such liability, except to the extent that the DGCL prohibits the elimination or limitation of liability of directors
for breaches of fiduciary duty. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&nbsp;145 of the DGCL provides that a corporation has the power to indemnify a director, officer, employee or
agent of the corporation and certain other persons serving at the request of the corporation in related capacities against expenses (including attorneys&#146; fees), judgments, fines and amounts paid in settlements actually and reasonably incurred
by the person in connection with an action, suit or proceeding to which he or she is or is threatened to be made a party by reason of such position, if such person acted in good faith and in a manner he or she reasonably believed to be in or not
opposed to the best interests of the corporation, and, in any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful, except that, in the case of actions brought by or in the right of the corporation, no
indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to the corporation unless and only to the extent that the Court of Chancery or other adjudicating court determines
that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnification for such expenses which the Court of Chancery or such other court shall deem proper.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation provides that we will indemnify each person who was or is a party or threatened to be made a party to any threatened,
pending or completed action, suit or proceeding, whether civil, criminal, administrative or investigative (other than an action by or in the right of us), by reason of the fact that he or she is or was, or has agreed to become, our director or
officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner, employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise (all such
persons being referred to as an Indemnitee), or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
attorneys&#146; fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding and any appeal therefrom if such
Indemnitee acted in good faith and in a manner he or she reasonably believed to be in, or not opposed to, our best interests, and, with respect to any criminal action or proceeding, he or she had no reasonable cause to believe his or her conduct was
unlawful. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our certificate of incorporation also provides that we will indemnify any Indemnitee who was or is a party to an action or suit by or in the
right of us to procure a judgment in our favor by reason of the fact that the Indemnitee is or was, or has agreed to become, our director or officer, or is or was serving, or has agreed to serve, at our request as a director, officer, partner,
employee or trustee of, or in a similar capacity with, another corporation, partnership, joint venture, trust or other enterprise, or by reason of any action alleged to have been taken or omitted in such capacity, against all expenses (including
attorneys&#146; fees) and, to the extent permitted by law, amounts paid in settlement actually and reasonably incurred in connection with such action, suit or proceeding, and any appeal therefrom, if the Indemnitee acted in good faith and in a
manner he or she reasonably believed to be in, or not opposed to, our best interests, except that no indemnification shall be made with respect to any claim, issue or matter as to which such person shall have been adjudged to be liable to us, unless
a court determines that, despite such adjudication but in view of all of the circumstances, he or she is entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that any Indemnitee has been successful, on the
merits or otherwise, he or she will be indemnified by us against all expenses (including attorneys&#146; fees) actually and reasonably incurred by him or her or on his or her behalf in connection therewith. If we do not assume the defense, expenses
must be advanced to an Indemnitee under certain circumstances. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In addition, we have entered into indemnification agreements with all of our directors and
executive officers. In general, these agreements provide that we will indemnify the executive officer or director to the fullest extent permitted by law for claims arising in his or her capacity as an executive officer or director of our company or
in connection with his or her service at our request for another corporation or entity. The indemnification agreements also provide for procedures that will apply in the event that an executive officer or director makes a claim for indemnification
and establish certain presumptions that are favorable to the executive officer or director. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We maintain a general liability insurance policy that covers
certain liabilities of our directors and officers arising out of claims based on acts or omissions in their capacities as directors or officers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Insofar
as the foregoing provisions permit indemnification of directors, executive officers, or persons controlling us for liability arising under the Securities Act of 1933, as amended, or the Securities Act, we have been informed that, in the opinion of
the SEC, such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.</P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;15.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Recent Sales of Unregistered Securities. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Set forth below is information regarding shares of our common stock, shares of our convertible preferred stock and stock options granted by us within the past
three years that were not registered under the Securities Act. Also included is the consideration, if any, received by us for such shares and options and information relating to the section of the Securities Act, or rule of the SEC, under which
exemption from registration was claimed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Issuances of Common Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On June&nbsp;18, 2021, we entered into a purchase agreement, or the Purchase Agreement, with Lincoln Park Capital Fund, LLC, or Lincoln Park, pursuant to which
we have the right to sell to Lincoln Park up to $15.0&nbsp;million in shares of common stock, subject to certain limitations, from time to time over the <FONT STYLE="white-space:nowrap">24-month</FONT> period commencing on the date that a
registration statement covering the resale of the shares is declared effective by the SEC. On June&nbsp;18, 2021, we issued 170,088 shares of common stock to Lincoln Park as consideration for its commitment to purchase our shares under the Purchase
Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On May&nbsp;9, 2019, concurrent with the closing of our initial public offering, we sold 1,500,000 shares of
our common stock at the initial per share public offering price of $10.00 in a private placement to New Enterprise Associates 16, L.P., or NEA. The aggregate gross proceeds to us from our private placement were $15.0&nbsp;million, before deducting
placement agent fees of $1.1&nbsp;million. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No underwriters were involved in the foregoing issuances of securities. The securities described in this
section&nbsp;(a) of Item&nbsp;15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in Section&nbsp;4(a)(2) under the Securities Act relative to transactions by an issuer
not involving any public offering, to the extent an exemption from such registration was required. All purchasers received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made
pursuant to a registration statement or an available exemption from such registration. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Issuances of Convertible Preferred Stock </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On January&nbsp;18, 2019, we issued and sold 6,849,315 shares of our Series C convertible preferred stock to seven investors for cash at a price per share of
$1.46 for an aggregate cash purchase price of $9,999,999.90. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On August&nbsp;30, 2018, we issued and sold 7,211,165 shares of our Series C convertible
preferred stock to seven investors for cash at a price per share of $1.46 for an aggregate cash purchase price of $10,528,300.90. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No underwriters were
involved in the foregoing issuances of securities. The securities described in this section (b)&nbsp;of Item 15 were issued to investors in reliance upon the exemption from the registration requirements of the Securities Act, as set forth in
Section&nbsp;4(a)(2) under the Securities Act and, in certain cases, Regulation D thereunder, relative to transactions by an issuer not involving any public offering, to the extent an exemption from such registration was required. All purchasers
received written disclosures that the securities had not been registered under the Securities Act and that any resale must be made pursuant to a registration statement or an available exemption from such registration. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(c) Stock Option Grants and Exercises </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Between
July&nbsp;1, 2018 and May&nbsp;7, 2019, we granted options to purchase an aggregate of 116,983 shares of common stock, with an exercise price of $9.12 per share, to our employees, directors, advisors and consultants pursuant to our 2012 Stock
Incentive Plan. Between July&nbsp;1, 2018 and May&nbsp;7, 2019, we did not issue shares of our common stock upon the exercise of stock options outstanding under our 2012 Stock Incentive Plan as no options were exercised during this time period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The stock options and the shares of common stock issued upon the exercise of stock options described in this section (c)&nbsp;of Item 15 were issued pursuant
to written compensatory plans or arrangements with our employees, directors and consultants, in reliance on the exemption provided by Rule 701 promulgated under the Securities Act, relative to transactions by an issuer not involving any public
offering, to the extent an exemption from such registration was required. All recipients either received adequate information about our company or had access, through employment or other relationships, to such information. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;16.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Exhibits and Financial Statement Schedules. </B></P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(a) Exhibits. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The exhibits to the registration
statement are listed in the Exhibit Index attached hereto and incorporated by reference herein. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>(b) Financial Statement Schedules. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No financial statement schedules are provided because the information called for is not required or is shown either in the financial statements or notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>Item&nbsp;17.</B></TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Undertakings. </B></P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(a)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The undersigned Registrant hereby undertakes: </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To file, during any period in which offers or sales are being made, a post-effective amendment to the
registration statement: </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any prospectus required by Section&nbsp;10(a)(3) of the Securities Act of 1933, as amended (the
&#147;Securities Act&#148;); </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To reflect in the prospectus any facts or events arising after the effective date of the registration statement
(or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in the
volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus
filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20&nbsp;percent change in the maximum aggregate offering price set forth in the &#147;Calculation of Registration
Fee&#148; table in the effective registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(iii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To include any material information with respect to the plan of distribution not previously disclosed in the
registration statement or any material change to such information in the registration statement; </P></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>provided, however</I>, that
paragraphs&nbsp;(a)(1)(i), (ii) and (iii)&nbsp;do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to
Section&nbsp;13 or Section&nbsp;15(d) of the Securities Exchange Act of 1934, as amended (the &#147;Exchange Act&#148;), that are incorporated by reference in the registration statement. </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purposes of determining any liability under the Securities Act, each such post-effective
amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at the time shall be deemed to be the initial <I>bona fide</I> offering thereof. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">To remove from registration by means of a post-effective amendment any of the securities being registered which
remain unsold at the termination of the offering. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="9%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">That, for the purpose of determining liability under the Securities Act to any purchaser,
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(i)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each prospectus filed by the Registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the
registration statement as of the date the filed prospectus was deemed part of and included in the registration statement; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="13%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(ii)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5), or (b)(7) as part of a registration
statement in reliance on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x)&nbsp;for the purpose of providing the information required by Section&nbsp;10(a) of the Securities Act shall be deemed to be part of and
included in the registration statement as of the earlier of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering described in the prospectus. As provided in Rule
430B, for liability purposes of the issuer and any person that is at that date an underwriter, such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement to which that
prospectus relates, and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof; <I>provided</I>, <I>however</I>, that no statement made in a registration statement or prospectus that is part
of the registration statement or made in a document incorporated or deemed incorporated by reference into the registration statement or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="18%">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">
prospectus that is part of the registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement that was made in the
registration statement or prospectus that was part of the registration statement or made in any such document immediately prior to such effective date. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(b)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each
filing of the Registrant&#146;s annual report pursuant to Section&nbsp;13(a) or 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan&#146;s annual report pursuant to Section&nbsp;15(d) of the Exchange Act) that
is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial <I>bona
fide</I> offering thereof. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(c)</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors,
officers and controlling persons of the Registrant pursuant to the indemnification provisions described herein, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as
expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling
person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its
counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final
adjudication of such issue. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Description</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Form</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">SEC Filing<BR>Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Filed&nbsp;with<BR>this<BR>Registration<BR>Statement</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519142949/d740290dex31.htm">Restated Certificate of Incorporation of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/9/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519142949/d740290dex32.htm">Amended and Restated <FONT STYLE="white-space:nowrap">By-laws</FONT> of the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/9/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex41.htm">Specimen stock certificate evidencing shares of common stock </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;5.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d153682dex51.htm">Opinion of Wilmer Cutler Pickering Hale and Dorr LLP </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex101.htm">Second Amended and Restated Investors&#146; Rights Agreement dated as of July&nbsp;14, 2017 </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex102.htm">2012 Stock Incentive Plan, as amended </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex103.htm">Form of Nonstatutory Stock Option Agreement under the 2012 Stock Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.3</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex104.htm">2019 Stock Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.4</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex105.htm">Form of Stock Option Agreement under 2019 Stock Incentive Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.5</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex106.htm">2019 Employee Stock Purchase Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.6</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000156459021015506/trvi-ex107_330.htm"><FONT STYLE="white-space:nowrap">Non-Employee</FONT> Director Compensation Policy </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/25/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.7</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519253605/d808144dex101.htm">Trevi Therapeutics, Inc. Executive Separation Benefits and Retention Plan </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">9/24/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex108.htm">Employment Agreement, dated December&nbsp;4, 2012, by and between the Registrant and Jennifer L. Good </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.8</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000156459020010996/trvi-ex1010_255.htm">Employment Agreement, dated December&nbsp;4, 2012, by and between the Registrant and Thomas R. Sciascia </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">10-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">3/16/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex1011.htm">Indefinite Term Employment Contract, dated August&nbsp;29, 2018, by and between the Registrant and Yann Mazabraud </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.11</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex1010.htm">Offer Letter, dated August&nbsp;29, 2018, by and between the Registrant and Yann Mazabraud </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.10</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex109.htm">Offer Letter, dated April&nbsp;23, 2018, by and between the Registrant and Christopher J. Seiter </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.9</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex1012.htm">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.12</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex1013.htm">Indenture of Lease, dated February&nbsp;6, 2013, by and between First Niagara Bank, N.A. and the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.13</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex1014.htm">First Amendment to Lease, dated December&nbsp;5, 2017, by and between the Registrant and 195 Church Street Associates, LLC </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.14</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.17&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex1015.htm">Exclusive License Agreement, dated as of May&nbsp;13, 2011, by and between the Registrant and Penwest Pharmaceuticals Co. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.15</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="57%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="10%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="9%"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exhibit<BR>No.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Description</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Form</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">SEC Filing<BR>Date</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">
<P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Filed&nbsp;with<BR>this<BR>Registration<BR>Statement</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.18&#134;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex1016.htm">Exclusive License Agreement between the Registrant and Rutgers, the State University of New Jersey, effective November&nbsp;6, 2018
</A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.16</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.19</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519138831/d643194dex1017.htm">Share Purchase Agreement, dated as of May&nbsp;6, 2019, by and between the Registrant and New Enterprise Associates 16, L.P. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1/A&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">5/7/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.17</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.20</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000156459020053330/trvi-ex101_80.htm">Loan and Security Agreement, dated as of August&nbsp;13, 2020, between Silicon Valley Bank and Trevi Therapeutics, Inc. </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">10-Q</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">11/12/2020</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">10.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.21</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312521195073/d195500dex991.htm">Purchase Agreement, dated as of June&nbsp;18, 2021, by and between the Registrant and Lincoln Park Capital Fund, LLC </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/21/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.22</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312521195073/d195500dex992.htm">Registration Rights Agreement, dated as of June&nbsp;18, 2021, by and between the Registrant and Lincoln Park Capital Fund, LLC </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">8-K</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">6/21/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">99.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>10.23</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000156459021035888/trvi-ex991_15.htm">First Amendment to Loan and Security Agreement, dated July&nbsp;6, 2021, by and between Silicon Valley Bank and the Registrant </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">8-K</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">7/7/2021</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">99.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="http://www.sec.gov/Archives/edgar/data/1563880/000119312519099340/d643194dex211.htm">List of Subsidiaries </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><FONT STYLE="white-space:nowrap">S-1&#094;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">4/5/2019</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">21.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d153682dex231.htm">Consent of Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>23.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="d153682dex51.htm">Consent of Wilmer Cutler Pickering Hale and Dorr LLP (included in Exhibit 5.1) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>24.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"><A HREF="#sig">Power of Attorney (included on signature page) </A></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">X</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#134;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Confidential treatment has been granted as to certain portions, which portions have been omitted and filed
separately with the Securities and Exchange Commission </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">&#094;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">SEC File <FONT STYLE="white-space:nowrap">No.&nbsp;333-230745.</FONT> </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant has duly caused this Registration Statement to be signed on its behalf
by the undersigned, thereunto duly authorized, in the City of New Haven, State of Connecticut on July&nbsp;7, 2021. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="99%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>TREVI THERAPEUTICS, INC.</B></TD></TR></TABLE></DIV> <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer Good</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Name: Jennifer Good</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="sig"></A>SIGNATURES AND POWER OF ATTORNEY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below hereby constitutes and appoints Jennifer Good and Christopher Galletta, and
each of them, as his or her true and lawful <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent with full power of substitution, for him or her in any and all capacities, to sign any and all
amendments to this registration statement (including post-effective amendments or any abbreviated registration statement and any amendments thereto filed pursuant to Rule&nbsp;462(b) increasing the number of securities for which registration is
sought), and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully
for all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">attorney-in-fact</FONT></FONT> and agent, or his substitute, may
lawfully do or cause to be done by virtue hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Act, this Registration Statement has been signed below
by the following persons in the capacities and on the dates indicated. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="39%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Signature</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Title</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center"><B>Date</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer Good</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Jennifer Good</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">President and Chief Executive Officer and Director (principal executive officer and principal financial officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;7, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Christopher Galletta</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Christopher Galletta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Controller (principal accounting officer)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;7, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ David Meeker, M.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">David Meeker, M.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Chairman of the Board</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;7, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ James Cassella, Ph.D.</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">James Cassella, Ph.D.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;7, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Dominick Colangelo</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Dominick Colangelo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;7, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Michael Heffernan</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Michael Heffernan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;7, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Edward Mathers</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Edward Mathers</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;7, 2021</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Anne VanLent</P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Anne VanLent</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">Director</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" NOWRAP ALIGN="center">July&nbsp;7, 2021</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">II-9 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>2
<FILENAME>d153682dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g153682g0701230531972.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;7, 2021 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 617 526 6000 (t) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">+1 617 526 5000
(f) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">wilmerhale.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trevi Therapeutics, Inc.
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">195 Church Street, 14th Floor </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">New Haven, Connecticut 06510
</P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">Re:</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><U>Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT></U> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion is furnished to you in
connection with a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-1</FONT> (the &#147;Registration Statement&#148;) filed with the Securities and Exchange Commission (the &#147;Commission&#148;) under the Securities Act of 1933, as
amended (the &#147;Securities Act&#148;), for the registration of an aggregate of 5,170,088 shares (the &#147;Shares&#148;) of common stock, par value $0.001 per share (the &#147;Common Stock&#148;), of Trevi Therapeutics, Inc., a Delaware
corporation (the &#147;Company&#148;) that have been or may be issued to Lincoln Park Capital Fund, LLC (the &#147;Selling Stockholder&#148;) pursuant to that certain Purchase Agreement, dated as of June&nbsp;18, 2021, by and between the Company and
the Selling Stockholder (the &#147;Purchase Agreement&#148;). All of the Shares are being registered for resale on behalf of the Selling Stockholder. The Shares consist of 170,088 outstanding shares of Common Stock that were issued to the Selling
Stockholder on June&nbsp;18, 2021 (the &#147;Outstanding Shares&#148;) and up to 5,000,000 shares of Common Stock (the &#147;Purchase Shares&#148;) that may be issued to the Selling Stockholder pursuant to the Purchase Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are acting as counsel for the Company in connection with the registration for resale of the Shares. We have examined signed copies of the Registration
Statement as filed with the Commission. We have also examined and relied upon the Purchase Agreement, minutes of meetings of the Board of Directors of the Company as provided to us by the Company, stock record books of the Company as provided to us
by the Company, the Certificate of Incorporation and <FONT STYLE="white-space:nowrap">By-Laws</FONT> of the Company, each as restated and/or amended to date, and such other documents as we have deemed necessary for purposes of rendering the opinions
hereinafter set forth. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In our examination of the foregoing documents, we have assumed the genuineness of all signatures, the authenticity of all
documents submitted to us as originals, the conformity to original documents of all documents submitted to us as copies, the authenticity of the originals of such latter documents and the legal competence of all signatories to such documents. </P>
<P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g153682dsp1.jpg" ALT="LOGO">
 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g153682g0701230531972.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Trevi Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;7, 2021 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"> Page
 2
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We assume that the appropriate action will be taken, prior to the offer and sale of the Shares by the Selling
Stockholder, to register and qualify the Shares for sale under all applicable state securities or &#147;blue sky&#148; laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We express no opinion herein
as to the laws of any state or jurisdiction other than the General Corporation Law of the State of Delaware and the federal laws of the United States of America. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon and subject to the foregoing, we are of the opinion that the Shares have been duly authorized, the Outstanding Shares are validly issued, fully
paid and nonassessable, and the Purchase Shares, when issued and paid for in accordance with the terms of the Purchase Agreement, will be validly issued, fully paid and nonassessable. It is understood that this opinion is to be used only in
connection with the offer and sale of the Shares while the Registration Statement is in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please note that we are opining only as to the matters
expressly set forth herein, and no opinion should be inferred as to any other matters. This opinion is based upon currently existing statutes, rules, regulations and judicial decisions, and we disclaim any obligation to advise you of any change in
any of these sources of law or subsequent legal or factual developments which might affect any matters or opinions set forth herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to
the filing of this opinion with the Commission as an exhibit to the Registration Statement in accordance with the requirements of Item 601(b)(5) of Regulation <FONT STYLE="white-space:nowrap">S-K</FONT> under the Securities Act and to the use of our
name therein and in the related Prospectus under the caption &#147;Legal Matters.&#148; In giving such consent, we do not hereby admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the
rules and regulations of the Commission. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very truly yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">WILMER CUTLER PICKERING HALE AND DORR LLP</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Stuart M. Falber</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Stuart M. Falber, a Partner</TD></TR>
</TABLE>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>3
<FILENAME>d153682dex231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-23.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 23.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Consent of Independent Registered Public Accounting Firm </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the caption &#147;Experts&#148; in the Registration Statement (Form <FONT STYLE="white-space:nowrap">S-1)</FONT>
and related Prospectus of Trevi Therapeutics, Inc. for the registration of 5,170,088 shares of its common stock and to the incorporation by reference therein of our report dated March&nbsp;25, 2021, with respect to the consolidated financial
statements of Trevi Therapeutics, Inc., included in its Annual Report (Form <FONT STYLE="white-space:nowrap">10-K)</FONT> for the year ended December&nbsp;31, 2020, filed with the Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">/s/ Ernst&nbsp;&amp; Young LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stamford, Connecticut </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">July&nbsp;6, 2021 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g153682dsp1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g153682dsp1.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M4AB+K)#L 5!@'D?,-OOGO0!7_M758[[['#!*B"=TC7[.<"+[/N3GI]_CK[4
M5(KW4H&CU$Q3RSOI]JL\AMSE29&\P[0.2H.< ?A0!M:9<:I-K1BN+C=:QVL;
M@BW*"1R7!Y/3 "''O[T 4TTH7_B/4W?S($AO(+A7$9!DVQ@85O3.0<9XR.]
M%?3]0OY=.AM;J&2T_P!##*D=H0LK?,'7@?)C XXZ]Z (-,U35;70[&U>">V:
M-8H7)MRXA3ROE88&3E@ ?[IX]Z +DUWJ[/<F8"5(;VVC2/[(<%3Y9=QGG@E^
M>V/:@"&XUO7+2.YG;YD"717?;E5C\N0",Y'JI/7KC/K0!KZ7?/J&BWLDES'<
ME6D4"-?F5?X58#^+!!./6@#$L[6ZCTOP>)@62%X]T8M&5HB(6'S>F#QR!S0
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M!D_2@!<T % !0!6DO[2$D27"(1(L1!/\;8P/J<B@":.:.4-Y;AMK%3CL1U%
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MI4UC=R2R.A!4J2N=TI+$[GSW'3_.* -:@#'OM$-[J$LQF"PR0XV8Y$H!"O\
M@"?R% % >&[PS>9)<0N6A99" 5W,RG=TYQN)/7\* )H/#CQJ'=XA.NP(RKC8
M [L0",=0V. /I0 VY\/RI;.\.))R<L!UE'R?*<D<?+Z]Z (K?P].8UF:WMXI
M"26B;H5\UF"'&?EP?S [4 7;'03:SP7#R(TL;@E@#PNQEV#VRP_(4 ;= !0
M4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 %
M!0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4
E % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % !0 4 % '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g153682g0701230531972.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g153682g0701230531972.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  0 'L# 2(  A$! Q$!_\0
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=OI7AC4KFQ@40PS2GRF=4^7.U@".G<<CGO0!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g153682g58r98.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g153682g58r98.jpg
M_]C_X  02D9)1@ ! 0(!>0%Y  #_[1MZ4&AO=&]S:&]P(#,N,  X0DE-! 0
M    &UZ^< 8X0DE-! 0      %8< 5H  QLE1QP"   "   < E  "')R-C X
M,#0R' (% #5-:6-R;W-O9G0@5V]R9" M(%1R979I("T@1EDR,#$Y(%!R;WAY
M(%-T871E;65N="!#;&5A;CA"24T$)0      $(?AQ-J+&#A7B0*>."8QT.0X
M0DE-!#H      .4    0     0      "W!R:6YT3W5T<'5T    !0    !0
M<W138F]O; $     26YT965N=6T     26YT90    !#;')M    #W!R:6YT
M4VEX=&5E;D)I=&)O;VP     "W!R:6YT97).86UE5$585     $       ]P
M<FEN=%!R;V]F4V5T=7!/8FIC    # !0 '( ;P!O &8 ( !3 &4 = !U '
M      IP<F]O9E-E='5P     0    !";'1N96YU;0    QB=6EL=&EN4')O
M;V8    )<')O;V9#35E+ #A"24T$.P     "+0   !     !       2<')I
M;G1/=71P=71/<'1I;VYS    %P    !#<'1N8F]O;       0VQB<F)O;VP
M     %)G<TUB;V]L      !#<FY#8F]O;       0VYT0V)O;VP      $QB
M;'-B;V]L      !.9W1V8F]O;       16UL1&)O;VP      $EN=')B;V]L
M      !"8VMG3V)J8P    $       !21T)#     P    !29" @9&]U8D!O
MX            $=R;B!D;W5B0&_@            0FP@(&1O=6) ;^
M      !"<F1456YT1B-2;'0               !";&0@56YT1B-2;'0
M          !2<VQT56YT1B-0>&Q 6             IV96-T;W)$871A8F]O
M; $     4&=0<V5N=6T     4&=0<P    !09U!#     $QE9G15;G1&(U)L
M=                %1O<"!5;G1&(U)L=                %-C;"!5;G1&
M(U!R8T!9            $&-R;W!7:&5N4')I;G1I;F=B;V]L      YC<F]P
M4F5C=$)O='1O;6QO;F<         #&-R;W!296-T3&5F=&QO;F<
M#6-R;W!296-T4FEG:'1L;VYG          MC<F]P4F5C=%1O<&QO;F<
M #A"24T#[0      $ .__C4  @ ! [_^-0 "  $X0DE-!"8       X
M        /X   #A"24T$#0      !    '@X0DE-!!D       0    >.$))
M30/S       )           ! #A"24TG$       "@ !          $X0DE-
M _4      $@ +V9F  $ ;&9F  8       $ +V9F  $ H9F:  8       $
M,@    $ 6@    8       $ -0    $ +0    8       $X0DE- _@
M '   /____________________________\#Z     #_________________
M____________ ^@     _____________________________P/H     /__
M__________________________\#Z   .$))300(       0     0   D
M  )      #A"24T$'@      !      X0DE-!!H      S4    &
M      !Y    ^          !                          $
M     /@   !Y                      $
M$     $       !N=6QL     @    9B;W5N9'-/8FIC     0       %)C
M=#$    $     %1O<"!L;VYG          !,969T;&]N9P          0G1O
M;6QO;F<   !Y     %)G:'1L;VYG    ^     9S;&EC97-6;$QS     4]B
M:F,    !       %<VQI8V4    2    !W-L:6-E241L;VYG          =G
M<F]U<$E$;&]N9P         &;W)I9VEN96YU;0    Q%4VQI8V5/<FEG:6X
M   -875T;T=E;F5R871E9     !4>7!E96YU;0    I%4VQI8V54>7!E
M $EM9R     &8F]U;F1S3V)J8P    $       !28W0Q    !     !4;W @
M;&]N9P          3&5F=&QO;F<          $)T;VUL;VYG    >0    !2
M9VAT;&]N9P   /@    #=7)L5$585     $       !N=6QL5$585     $
M      !-<V=E5$585     $       9A;'1486=415A4     0      #F-E
M;&Q497AT27-(5$U,8F]O; $    (8V5L;%1E>'1415A4     0      "6AO
M<GI!;&EG;F5N=6T    /15-L:6-E2&]R>D%L:6=N    !V1E9F%U;'0    )
M=F5R=$%L:6=N96YU;0    ]%4VQI8V5697)T06QI9VX    '9&5F875L=
M  MB9T-O;&]R5'EP965N=6T    115-L:6-E0D=#;VQO<E1Y<&4     3F]N
M90    ET;W!/=71S971L;VYG          IL969T3W5T<V5T;&]N9P
M   ,8F]T=&]M3W5T<V5T;&]N9P         +<FEG:'1/=71S971L;VYG
M   X0DE-!"@       P    "/_         X0DE-!!$       $! #A"24T$
M%       !     0X0DE-! P     $.D    !    H    $X   '@  "20
M$,T &  !_]C_[0 ,061O8F5?0TT  O_N  Y!9&]B90!D@     '_VP"$  P(
M" @)" P)"0P1"PH+$14/# P/%1@3$Q43$Q@1# P,# P,$0P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P!#0L+#0X-$ X.$!0.#@X4% X.#@X4$0P,# P,
M$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_  !$( $X
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M&P;0Q[($?F/]RY\!=S]>OJ@S%&;]8!E%[[[V'[.6-:UOJ%E7\[NW>U<3M ,
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MZ;6^S):/TV0&[FU3JVM@=[++_P [_1U)/Z#3]7&.ZVS+=9]BIM<ZJUK0UP
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ >0#X P$1  (1 0,1 ?_$ !\
M   %!0$!               '" D* @,$!08+ ?_$ %,0  $$ 0($ P0&! D'
M" L   $" P0%!@<1  @2(0D3,10B05$5%B,R87$7@9&Q"B0F,T)2<K+!&!F2
MH<+1\"4G-#4V4U>".$-$8H.$EJ*ST]7_Q  < 0 !! ,!
M P4&!P$"! C_Q !-$0 ! @4# @,%! 4(" 8!!0 ! A$  P0A,0420091(F%Q
M$Q0R@9$'0J&Q%2-2P=$6)#-B<I+A\!<E-#5#5*+21%."D[+Q="9U@\35_]H
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M5!-;Z271 U6G+,^D4[2V*IHYQD8]6L7P+4Z>ZZEU_L:7592J6K4F\XAI*B[
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MWV+7,7S&*/3^G_6U0![?\[>?[*_$A60'N1^.P] /GDZ9IX_\+3'AQ(DDV_\
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MNHL ZF2=ZF^\XR0<E_.A:] IZR?)EL *O:D%@ GQ-+ \+I%BP8%[L?%!/&-
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MU*\4U.T.RB4H>Q<%OO'BW+Q'/9M\6Z4?1VA3\E!]Q+DIRQ=5U;]RH+@303Z
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MOT^N_P ^*DB^H8(\=G3_ #K(-/M!LRPN3!K&J7-,GQ+(+:5&$Q^+"R:F@VL
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M4] T\VR71!C3YK:)EB\ %$1:J N7-F;[)2S&"E[!.W#AJ%4*.FJ:D>%0\25
MLIK,Q#$?4!F&,\&FT1KZJGH[**SM(+$'^TY(:[.0;=HF^8=BU1A6)XUAV/Q6
MX=)B]#5XW3Q4DD1JVH@1H4)@K"0>M$6.D*6 -U@;[G;BE9DQ4V8N:HE2EG<5
M*)4HOR5%R?F3'HF5+3)E(E(2$I0  E("4ANR4LD?(".LXTA2$(^(=<HI.6NZ
MEO)ZXRLMPB+*^*D,R<DC-EY!)[*1ONE8((/=)W&_#WH"!-U*G20%!U%F!'W
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M(('P&WE]_4;I&W?<[]]O7\>,*WDL4CYY ![X-[$>L 2A5PHCT?BX%@20_?\
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MY/4%IXN;1ZT5^E2*L*/MC927-R.]@"'#,1W# &/.W4&EG2M9JJ1*094US))
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M>L8Q X;C62=Q4$(*F^(I&YLNY)+,UB>Q O'<BAJ% )*Y:4LS$! =P7 &X,>
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MCPI4\^X\L;./2'GB-^K;SB3[RB/>W)).QVW/4=]^'-"3[-F^CY)!(^7!#,W
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MI6I#C;LU27 LI4.D[<.XZSUL%R:=1OXBBY=LN>[FV(8T?9]TVA(0F77)0#\
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MP+.S&ULX2D=%Z13SO>4FI6NSA<TJ!-R^U@0;\6[^;GS;#;2/+0G9(VV]-T[
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MU3J,[WFJ]G[7;M:4D!(2"2P#EKEF=L,,P_:9IM-I--[K2>U]D%E;S5%2BH@
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M=IIPEG</NJ]2K<I:_JDW0OM>J*V7H\_5=^BI!I:0B9.7_,RJ\ME;@2ZB%)4
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H_>_M']T9.$^G[S&0?5/Y_P"!XVC$6T>A_-/[^,#*O7]P@B[QF"/_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
